Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 26, 2026.

Response Inhibition and Interference Control in Obsessive–Compulsive Spectrum Disorders

Laura S. van Velzen, Chris Vriend, Stella J. de Wit and 1 more

Frontiers in Human Neuroscience · 2014 · Review

doi:10.3389/fnhum.2014.00419

Abstract

Over the past 20 years, motor response inhibition and interference control have received considerable scientific effort and attention, due to their important role in behavior and the development of neuropsychiatric disorders. Results of neuroimaging studies indicate that motor response inhibition and interference control are dependent on cortical-striatal-thalamic-cortical (CSTC) circuits. Structural and functional abnormalities within the CSTC circuits have been reported for many neuropsychiatric disorders, including obsessive-compulsive disorder (OCD) and related disorders, such as attention-deficit hyperactivity disorder, Tourette's syndrome, and trichotillomania. These disorders also share impairments in motor response inhibition and interference control, which may underlie some of their behavioral and cognitive symptoms. Results of task-related neuroimaging studies on inhibitory functions in these disorders show that impaired task performance is related to altered recruitment of the CSTC circuits. Previous research has shown that inhibitory performance is dependent upon dopamine, noradrenaline, and serotonin signaling, neurotransmitters that have been implicated in the pathophysiology of these disorders. In this narrative review, we discuss the common and disorder-specific pathophysiological mechanisms of inhibition-related dysfunction in OCD and related disorders.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 26, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

Response inhibition, the ability to suppress pre-potent behavior that is inappropriate or no longer required, is critical for goal-directed behavior in everyday life (Chambers et al., ). Over the past decades, researchers have shown increased interest in response inhibition. Response inhibition is considered an operationalization of certain aspects of impulsivity and compulsivity (Bari and Robbins, ). Impulsivity is commonly defined as a tendency to act on impulses, acts performed immediately and without voluntary control, whereas compulsivity is the tendency to repeat specific behavior and to be unable to inhibit the behavior even when it is no longer appropriate (Bari and Robbins, ). Due to the importance of response inhibition in everyday life, many neuropsychological paradigms have been developed to probe inhibitory performance. In these paradigms, subjects are asked to respond to a target stimulus, but withhold this response to irrelevant or distracting stimuli, or distracting stimulus characteristics (Nigg, ).

Response inhibition is not a unitary construct and consists of motor response inhibition and interference control. Motor response inhibition involves the inhibition of pre-potent and automatic motor responses, and can be further differentiated into action restraint (or action suppression) and action cancelation (Schachar et al., ). The Go/No Go task (Donders, ) is considered to probe action restraint, whereas the Stop-signal task (Logan, ) measures action cancelation (see Figure 1 for a description of these tasks). Interference control on the other hand, refers to the cognitive control needed to prevent interference due to competition of relevant and irrelevant stimuli or stimulus characteristics (Nigg, ). Several tasks including the Stroop task, the Flanker task and the Simon task are measures of interference control (see Figure 1). It has been proposed that the inhibitory load is highest in the Stop-signal task, as the response that needs to be suppressed has already been initiated (Schachar et al., ). Contrary to the motor response inhibition tasks, interference control tasks may also rely on response selection processes (Nee et al., ). It has been suggested that interference control, action restraint, and action cancelation represent early, intermediate, and late processes of response inhibition, respectively (Sebastian et al., ).

The symptoms of obsessive–compulsive and related disorders within the impulsive–compulsive spectrum are characterized by a failure to inhibit certain behaviors, e.g., washing hands, pulling hair, motor tics, or impulsive actions. Response inhibition might therefore be a suitable measure to investigate the neural substrates of these shared symptoms. In this narrative review, we will provide an overview of studies that have examined the neuroanatomical and functional underpinnings of response inhibition impairment in healthy subjects and patients with these disorders but this review by no means constitutes an exhaustive account of the current literature. We will focus on the shared mechanisms that may underlie the inhibitory dysfunction and symptoms of these disorders. Pharmacological and genetic alterations are also addressed and focus on the dopamine, serotonin, and noradrenalin system. We acknowledge that other neurotransmitters, such as glutamate and gamma-Aminobutyric acid, are also important for response inhibition and the pathophysiology obsessive–compulsive and related disorders (MacMaster et al.,; Turner et al.,; van Minnen et al.,; DeVito et al.,; Starck et al.,; Silveri et al., ), but discussion of all these neurotransmitters would considerably lengthen this review.

Neuroimaging of response inhibition

Neuroimaging studies in healthy controls have revealed the neural substrates of response inhibition [for excellent reviews, see Robbins, Chambers et al., and Aron]. While major contributions to our understanding of response inhibition come from electrophysiological studies, in this review, we will focus on neuroimaging studies. Readers interested in the electrophysiology of response inhibition are directed to Huster et al..

In brief, response inhibition activates a network of mainly right lateralized frontal brain areas. The inferior frontal gyrus (IFG) and pre-supplementary motor area (pre-SMA) are key components (Aron et al.,; Chambers et al.,; Floden and Stuss,; Cai et al., ), and the neural stop-signal is then sent from these frontal areas to the motor cortex through cortico-striatal–thalamic–cortical (CSTC) projections (Chambers et al., ).

The subcomponents of response inhibition are found to depend on overlapping, yet distinct, brain areas. Interference inhibition, action restraint and action cancelation are all associated with activation of the IFG, anterior insula, anterior cingulate cortex (ACC), dorsolateral prefrontal cortex (DLPFC), pre-SMA, and parietal regions (Wager et al.,; Nee et al.,; Sebastian et al., ). When inhibitory task load increases, activation of frontal–striatal regions increases and additional inhibition-related brain areas are recruited (Blasi et al.,; Swick et al.,; Sebastian et al., ). However, each task recruits distinct brain areas as well, depending on the unique cognitive processes that they represent. Regions involved in response selection, including the parietal cortex, for instance, are activated to a greater extent during interference control tasks and action restraint (Rubia et al.,; Sebastian et al., ).

Neurotransmitters in response inhibition

In addition to differences in neural activation, differences in the neurotransmitter systems underlying interference control, action restraint, and action cancelation have also been observed. Current studies suggest that interference control is dependent on serotonin and dopamine neurotransmission. Depletion of serotonin and dopamine has been shown to decrease interference effects on incongruent trials, and thus improve performance, during the Stroop task (Schmitt et al.,; Scholes et al., ). Decreases in serotonin may improve performance by increasing arousal and attention (Scholes et al., ). Increased activation of the DLPFC and ACC was observed during performance of a Stroop task after serotonin depletion (Horacek et al., ). Stroop performance was positively correlated with serotonin transporter (SERT) binding in the right DLPFC as well (Madsen et al., ). However, contradicting results have also been reported, as neuroimaging studies showed that decreased dopamine transporter (DaT) binding in the striatum in women (Mozley et al., ) and decreased postsynaptic striatal D2-receptor availability was associated with poor performance on a Stroop task (Volkow et al., ). Administration of a dopamine D2 agonist decreased interference, and thereby improved performance on the Stroop task (Roesch-Ely et al., ). Based on the available literature in healthy subjects it seems that both serotonin and dopamine are important for interference control.

Action restraint (Go/No Go task) seems to be primarily mediated by serotonin [for a review of evidence, see Eagle et al.]. Serotonin depletion has been shown to decrease activation of the IFG during inhibition and decreases activation of the medial prefrontal lobe during error monitoring in the Go/No Go task (Rubia et al.,; Evers et al., ). Administration of a serotonin 2C receptor agonist (Anderson et al., ) or mirtazapine (Vollm et al., ), which acts on both the noradrenalin and serotonin system, increased inhibition-related activation of the right IFG. Nevertheless, dopamine may play a role in action restraint as well since methylphenidate, a dopamine re-uptake inhibitor, improved performance on the Go/No Go task and led to decreased task-related striatal activation (Vaidya et al., ).

Several lines of evidence support an important role for dopamine in action cancelation. Increased Dopamine D2/3-receptor availability in the striatum is associated with better Stop-signal task performance, i.e., shorter stop-signal reaction time (SSRT), and correlates positively with inhibition-related activation of the dorsal caudate and putamen (Ghahremani et al., ). Also, administration of a D2-receptor agonist improved action cancelation (Nandam et al., ). Administration of methylphenidate and atomoxetine, which both target the dopamine and noradrenalin system, by inhibiting the re-uptake from the synaptic cleft, decreased SSRT in humans and in animals, raising the possibility that noradrenalin is involved in motor response inhibition as well (Chamberlain et al.,; Eagle et al.,; Bari et al.,; Nandam et al., ). Serotonin does not seem to mediate performance of the Stop-signal task, as use of selective serotonin re-uptake inhibitors (SSRIs) and serotonin depletion did not affect action cancelation in humans or in animals (Clark et al.,; Chamberlain et al.,; Bari et al.,; Eagle et al.,; Drueke et al., ).

To summarize, interference control seems to be mediated by both serotonin and dopamine. Action restraint seems to be predominantly mediated by serotonin, whereas action cancelation seems to be mediated by dopamine and noradrenalin. More detailed information on the neuropharmacology of response inhibition is provided by Dalley and Roiser and Bari and Robbins.

Genes in response inhibition

Several gene-association studies have examined the relationship between genes involved in the dopaminergic and serotonergic systems and response inhibition. Genetic polymorphisms in the dopamine D4-receptor gene (DRD4), associated with reduced functional activity (Asghari et al., ), have been related to decreased performance on the Stop-signal task (Congdon et al., ), although conflicting results have also been reported (Kramer et al., ).

The DRD2 gene codes for the dopamine receptor D2. The presence of a TaqIA allele, which has been linked to decreased availability of striatal D2-receptors (Thompson et al., ), was associated with poor response inhibition in the Stop-signal task (White et al., ). A second polymorphism, which has been associated with decreased cortical and thalamic D2-receptor availability (Hirvonen et al., ), was also related to poor action cancelation (Colzato et al., ).

Genetic polymorphisms that increased expression of the DaT have been associated with impaired performance on an interference control task (Cornish et al., ) and decreased brain activation in the STN and pre-SMA during action cancelation (Congdon et al., ). Furthermore, two novel single nucleotide polymorphisms in the DaT gene predicted individual SSRT (Cummins et al., ) and genotype of one of these polymorphisms predicted activation of frontal areas and the caudate nucleus during task performance.

Polymorphisms in catechol-O-methyltransferase (COMT) and monoamine oxidase A (MAO-A) genes, coding for enzymes playing a role in neurotransmitter metabolism, have been associated with normal variations in inhibition-related activity as well. COMT is involved in the degradation of dopamine and noradrenalin and MAO-A is involved in degradation of dopamine, noradrenalin, and serotonin. A polymorphism of COMT with decreased function (Chen et al., ), was associated with increased activation of the IFG during action cancelation (Congdon et al., ) and decreased interference inhibition (Solis-Ortiz et al., ), although conflicting results have also been reported (Kramer et al., ). Polymorphisms of the MAO-A gene, which increase MAO-A activity, were associated with increased activity in the right IFG and ACC and decreased activity in the superior parietal cortex during action restraint (Passamonti et al., ).

Gene-association studies have focused on genes involved in serotonergic transmission as well. Serotonin synthesis in the brain is regulated by tryptophan-hydroxylase-2 (TPH-2) (Walther and Bader, ). Individuals homozygous for the T-allele of a polymorphism in the TPH-2 gene showed increased SSRT in the Stop-signal task (Stoltenberg et al., ). A second study found that two other polymorphisms in the TPH-2 gene were associated with reduced brain activity during action restraint in an EEG study (Baehne et al., ). Lastly, Osinsky et al. found that a polymorphism located in the promotor region of the TPH-2 gene, affected reaction time during performance of a Stroop task. Interpretation of these findings is, however, challenging as it is uncertain how these polymorphisms affect serotonin levels.

Polymorphisms in the SERT gene (SLC6A4) that decrease the rate of re-uptake from the synaptic cleft, were associated with decreased interference inhibition (Holmes et al., ), but not to action cancelation (Clark et al., ). Participants with a decreased function polymorphism in SERT also showed increased rostral ACC activation in response to errors and decreased activation of the dorsal ACC in response to conflict during the Flanker task (Holmes et al., ).

Intermediate summary

In summary, current evidence suggests that response inhibition is dependent on brain areas in the CSTC circuits and activation in these circuits increases with increasing inhibitory load. Proper function of these CSTC circuits depends on a complex interplay between dopamine, serotonin, and noradrenalin, although the weight of their importance may differ between the subcomponents of response inhibition. While reducing levels of serotonin and dopamine appears to ameliorate interference control, increasing dopamine levels appears to ameliorate action restraint and action cancelation. Gene-association studies have primarily reported that polymorphisms associated with decreased dopamine signaling are also associated with decreased motor response inhibition performance.

Structural and functional alterations in CSTC circuits and altered serotonin, noradrenalin, and dopamine transmission may underlie response inhibition deficits in obsessive–compulsive disorder (OCD) patients and in patients with related disorders.

Obsessive–Compulsive Disorder and Inhibition

Obsessive–compulsive disorder is an anxiety disorder that affects 2–3% of the population and causes severe impairment in social and occupational functioning (Ruscio et al., ). The disorder is characterized by distress- and anxiety provoking obsessions (repetitive intrusive thoughts) and compulsions (repetitive ritualistic behavior), which are performed to diminish anxiety (American Psychiatric Association, ). These symptoms are common, as more than 25% of the population experiences sub-clinical obsessions or compulsions in their lives (Ruscio et al., ). Pharmacotherapy for OCD consists mainly of SSRIs, which suggests involvement of the serotonin system in the pathophysiology of the disorder. Nevertheless, an estimated 40–60% of patients does not respond to this treatment and require additional treatment with atypical antipsychotics, which affects both the serotonergic and dopaminergic system (Denys et al.,; Fineberg et al., ). Neuroimaging studies have strengthened the notion of serotonergic dysfunction in OCD by providing evidence for reduced availability of SERTs in the midbrain, thalamus, and brainstem and reduced availability of serotonin 2A receptors in prefrontal, parietal, and temporal brain regions (Hesse et al.,; Perani et al., ). Abnormalities in the dopamine system have also been observed in OCD patients, such as increased DaT levels in the striatum and reduced availability of the D1- and D2-receptors in the striatum (Kim et al.,; Denys et al.,; van der Wee et al.,; Olver et al., ).

In the past several years, research interest has focused on response inhibition as a model of OCD symptoms (Chamberlain et al., ). In support of this, deficits in interference control, e.g., increased reaction times during incongruent trials, have been described in OCD (Bannon et al.,; Penades et al.,; Nabeyama et al.,; Nakao et al.,; Schlosser et al., ). A number of studies have used interference control paradigms in OCD research during functional neuroimaging (see Table 1; Fitzgerald et al.,; Nakao et al.,,; van den Heuvel et al.,; Viard et al.,; Nabeyama et al.,; Woolley et al.,; Page et al.,; Schlosser et al.,; Huyser et al.,; Rubia et al.,; Marsh et al., ). Some studies reported hyperactivation of the ACC in adults and children with OCD following errors and interference control (Fitzgerald et al.,; Huyser et al., ), while others reported hypoactivation of the ACC (Nakao et al.,; Rubia et al., ). Altered inhibition-related brain activation has also been observed in the pre-SMA (Fitzgerald et al.,; Rubia et al., ) and insular cortex (Huyser et al., ). Increased activation in frontal–striatal regions, including the IFG and putamen, was seen in OCD patients during performance of a Simon task (Marsh et al., ).

Abnormalities in activation during interference control tasks have also been observed at a network level. Schlosser et al. used dynamic causal modeling (DCM) to examine functional connectivity in a fronto-cingulate network during performance on a Stroop task, and found increased connectivity between the DLPFC and ACC in OCD patients compared with healthy controls. Increased functional connectivity between the putamen and the inferior parietal cortex, caudate, thalamus, and frontal areas was observed in patients during performance of a Simon task (Marsh et al., ).

Impaired action cancelation and action restraint has been described for OCD (Chamberlain et al.,; Penades et al., ); patients showed increased SSRT (i.e., slower inhibition) in the Stop-signal task and higher error rates on the Go/No Go task compared with healthy control subjects. Deficits in motor response inhibition were also observed in unaffected first-degree relatives of OCD patients (Chamberlain et al.,; Menzies et al., ), suggesting that motor response inhibition may be considered an endophenotype [a trait that is heritable and co-segregates with the illness in families (Gottesman and Gould, )] of OCD patients.

Structural neural correlates of impaired motor response inhibition in OCD patients have been identified. Deficits in action cancelation in OCD patients and first-degree relatives were associated with increased gray matter volume in the ACC, putamen, caudate, amygdala, parietal areas, and the cerebellum, and decreased gray matter volume in the OFC, IFG, ACC, premotor cortex, and regions in the temporal cortex (Menzies et al., ).

Functional neural correlates of motor response inhibition impairments in OCD have also been identified (see Table 2; Maltby et al.,; Roth et al.,; Woolley et al.,; Page et al.,; Rubia et al.,; de Wit et al.,; Kang et al., ). Decreased task-related activation is seen in the CSTC circuits during inhibition in OCD patients (Roth et al.,; Woolley et al.,; Page et al.,; Rubia et al.,; de Wit et al.,; Kang et al., ), although, one study reported increased activation of these regions (Maltby et al., ). In the largest study to date, de Wit et al. found decreased activation of the IFG and inferior parietal cortex during inhibition in unmedicated OCD patients and increased activation of the left pre-SMA. This pre-SMA hyperactivation was present in their unaffected siblings as well. Activation of the pre-SMA correlated negatively with SSRT in patients and siblings, indicating that hyperactivation of the pre-SMA may be considered a compensatory mechanism. Overall, the most consistent finding is decreased activation of the DLPFC, IFG, striatum, and thalamus in OCD patients during inhibition (Roth et al.,; Woolley et al.,; Page et al.,; Rubia et al.,; de Wit et al., ).

In a recent study, we examined functional connectivity during performance of the Stop-signal task in unmedicated adult OCD patients, their unaffected siblings, and healthy controls (van Velzen et al., under review). We performed psychophysiological interaction (PPI) analyses and DCM and found abnormal connectivity between the IFG and amygdala in patients and their siblings, suggesting that this pattern of connectivity is an endophenotype. Limbic activation may interfere with CSTC circuit activation in OCD. We did not find evidence for altered connectivity between the IFG, pre-SMA, and striatum during inhibition. These results warrant replication in other samples.

Two studies have investigated the effects of pharmacological treatment for OCD on response inhibition. Treatment with SSRI’s increased task-relevant brain activation during performance of an interference control task along with symptom improvement (Nakao et al., ). However, due to the study design, it remains unknown if this change in activation occurs secondary to symptom improvement or due to the pharmacological treatment. A second study reported increased activation of multiple cortical and subcortical brain areas during a Go/No Go task in OCD patients treated with SSRIs compared to OCD patients who were not treated with SSRIs (Roth et al., ). However, this study was crossectional, included small patient groups and did not study the relationship with disease severity.

In summary, OCD patients show impairment in both interference control and motor response inhibition. Prefrontal and other brain areas within the CSTC circuits appear to be hyperactive during interference control, although results have been inconsistent. As task load increases during action restraint and action cancelation, CSTC areas generally become hypoactive compared with controls, although some compensation may occur. Decreased serotonin and increased dopamine transmission in CSTC circuits may underlie the response inhibition deficits. The presence of, and functional correlates of response inhibition deficits have also been investigated in disorders related to OCD, such as Tourette’s syndrome (TS), trichotillomania (TTM), and attention-deficit hyperactivity disorder (ADHD), enabling the disorder specificity of these cognitive dysfunctions and enabling comparison of these inhibition deficits across these disorders.

Tourette’s syndrome

Gilles de la Tourette’s syndrome, also known as Tourette’s syndrome, is a neurodevelopmental disorder characterized by motor tics and vocal tics (American Psychiatric Association, ). TS affects between 0.4 and 1% of the population (Swain et al.,; Robertson, ).

Like in OCD, dysfunction of the serotonergic and dopaminergic systems is implicated in the pathophysiology of TS [for a review, see Steeves and Fox]. Several clinical trials have shown that administration of dopamine antagonists, such as risperidone and haloperidol, are effective in suppressing tics in most patients (Bloch et al.,; Roessner et al., ). Neuroimaging studies have reported decreased availability of the D2 and D3-receptors in cortical (OFC, ACC, insula, temporal, and occipital cortex) and subcortical areas (thalamus and hippocampus) (Gilbert et al.,; Steeves et al., ) and increased striatal DaT availability (Malison et al.,; Muller-Vahl et al.,; Cheon et al.,; Serra-Mestres et al.,; Liu et al., ), although conflicting results have also been reported (Singer et al.,; Hwang et al., ). Neuroimaging of the serotonergic system in TS has shown increased binding of the serotonin 2A-receptor in many cortical (OFC, ACC, insula, temporal lobe, parietal lobe, and occipital lobe) and subcortical areas (thalamus, caudate, and hippocampus) (Haugbol et al., ) and increased SERT availability in the striatum and midbrain (Wong et al., ).

There is increasing evidence for frontal–striatal dysfunction in TS [for reviews, see Albin and Mink and Felling and Singer]. For instance, symptom severity correlated negatively with the degree of activation of CSTC circuits during tic suppression (Peterson et al., ) and prefrontal cortical thickness (Draganski et al., ) and volume of prefrontal CSTC areas was decreased in TS patients compared with healthy controls (Draganski et al., ).

More than 90% of all patients with TS also have co-morbid psychiatric disorders, most often OCD or ADHD (Robertson, ). It has been estimated that between 45 and 60% of TS patients suffer from OCD as well (Ghanizadeh and Mosallaei, ). As in OCD, many studies have investigated whether the involuntary motor symptoms in TS are related to motor response inhibition and interference control. Evidence for this, however, has been mixed; as some studies report impaired performance (Baron-Cohen et al.,; Crawford et al.,; Rankins et al.,; Channon et al.,; Eichele et al., ), especially with increasing task demands, while others do not (Ozonoff et al.,; Ozonoff and Jensen,; Hershey et al.,; Verte et al.,; Watkins et al.,; Channon et al.,; Ray Li et al.,; Marsh et al.,; Raz et al.,; Sukhodolsky et al., ). These studies often included TS patients with co-morbid disorders and patients often used psychotropic medication. A meta-analysis of four studies using the Stop-signal task in TS found mild inhibitory deficits (Lipszyc and Schachar, ).

While evidence for behavioral impairment is not straightforward, inhibition-related brain activity seems to be altered in TS (see Table 3). With increasing age, patients with TS, compared with healthy controls, show increased recruitment of CSTC regions during interference control (Raz et al., ). Greater activation of CSTC areas, which was observed in TS patients during interference inhibition, might be considered a compensatory mechanism (Marsh et al., ). During motor response inhibition, patients with TS showed increased inhibition-related frontal brain activity in an event-related potential (ERP) study (Johannes et al., ). The authors noted that compensatory brain activation may explain why studies have not consistently observed response inhibition deficits in TS patients. No difference was found in brain activation between patients and controls during performance of a Go/No Go task, although the sample size was limited (Hershey et al., ). No study has yet investigated the direct effects of pharmacological treatment on behavioral or functional measures of response inhibition in TS, although, see Wylie et al..

In summary, behavioral inhibitory deficits may be limited to a subgroup of Tourette’s patients, as compensatory brain activation during inhibition may conceal behavioral deficits in response inhibition in some patients. Increased dopamine transmission in CSTC circuits may underlie the deficits in response inhibition.

Trichotillomania

Trichotillomania is an obsessive–compulsive related disorder (American Psychiatric Association, ). Patients with this disorder experience an urge to pull out their hair, which causes distress and functional impairment. Due to similarities between TTM and OCD, TTM was historically treated with SSRIs. Although initially considered effective in TTM (Stein et al., ), more recent studies report that SSRIs are ineffective in TTM (Streichenwein and Thornby,; van Minnen et al., ) or only effective in a specific subgroup of TTM patients (Stanley et al.,; Gadde et al., ). More recent clinical trials showed that treatment with atypical antipsychotics, such as olanzapine and aripiprazole, which exert their effects on among others, the serotonergic and dopaminergic system, are more promising (Van Ameringen et al.,; White and Koran, ).

It has been suggested that TTM symptoms originate from CSTC circuit dysfunction (Mataix-Cols and van den Heuvel, ). In support of this hypothesis, structural abnormalities in frontal areas and regions of the striatum have been observed in TTM (Chamberlain et al., ). As patients have difficulty suppressing a motor response, i.e., pulling out their hair, deficits in response inhibition may underlie the symptoms of this disorder (Chamberlain et al., ).

Research on response inhibition in TTM is limited and conflicting. While performance of a related cognitive control task was unaltered, TTM patients showed deficits in interference control in the Stroop task (Stanley et al.,; Bohne et al., ). Deficits in action cancelation have been reported, and the degree of impairment correlated with disease severity (Chamberlain et al., ). Impairment in action restraint was limited to a distinct subgroup of patients with an early onset of the disorder (Bohne et al., ).

The neural or pharmacological substrates of response inhibition deficits in TTM have not yet been fully elucidated, as no inhibition-related neuroimaging studies have been performed in this patient group. Nor have there been any studies on the effects of pharmacological treatment on response inhibition. TTM patients do, however, exhibit structural abnormalities in CSTC circuit regions associated with inhibition, for instance in the striatum, IFG, SMA, and prefrontal areas (Grachev,; O’Sullivan et al.,; Chamberlain et al., ), which may underlie response inhibition impairment in TTM.

Attention-deficit hyperactivity disorder

Attention-deficit hyperactivity disorder is a neuropsychiatric disorder characterized by hyperactivity, inattentiveness, and impulsiveness (American Psychiatric Association, ). It is a common disorder, as it is thought to affect almost 10% of school-aged children (Froehlich et al., ). The neuropharmacology of ADHD is complex and still not well-understood. Current evidence suggest that ADHD is characterized by deficits in the noradrenalin and dopamine systems [for a review, see McAlonan et al.], although some studies show additional involvement of the serotonergic (Oades et al., ) system. Pharmacotherapeutic treatment of ADHD with methylphenidate, amphetamines, or atomoxetine is effective in treating symptoms, presumably through increasing extracellular levels of dopamine and noradrenalin [see Prince for a review].

Patients with ADHD show behavioral impairments on a number of interference control tasks, including the Simon task and the Flanker task (Rubia et al.,; Sebastian et al., ). Activation of the ACC, IFG, thalamus, SMA, striatum, and inferior parietal cortex is decreased in ADHD patients during interference control (see Table 4). A recent meta-analysis revealed decreased activation of CSTC areas, including the right IFG, insular cortex, right caudate nucleus, left inferior parietal cortex, and left ACC in ADHD patients during performance of the Stroop and the Simon task (Hart et al., ).

Motor response inhibition is also affected in ADHD. A meta-analysis of 24 Stop-signal paradigm studies showed increased SSRT and mean GO reaction times in ADHD patients (Alderson et al., ). Structural abnormalities have been observed in CSTC circuit areas, including the IFG, caudate, and globus pallidus (Durston,; Sowell et al.,; Batty et al.,; Depue et al.,; Frodl and Skokauskas, ), leading some to argue that altered brain structure of these areas may underlie the impairments in response inhibition (Chambers et al., ). Gray matter volume of the right IFG, ACC, caudate nucleus, medial temporal lobe, and globus pallidus correlated negatively with task performance in patients (Casey et al.,; McAlonan et al., ). Functional neuroimaging studies show reduced inhibition-related activation of the caudate nucleus, IFG, and SMA, and increased activation of areas in the temporal and parietal lobe in children and adults with ADHD (see Table 5; Schulz et al.,; Tamm et al.,; Booth et al.,; Rubia et al.,; Suskauer et al.,; Dibbets et al.,; Dillo et al.,; Kooistra et al.,; Mulligan et al.,; Spinelli et al., ). A recent meta-analysis of 21 response inhibition studies revealed hypoactivation of the right ACC, right IFG, right insular cortex, right thalamus, left caudate nucleus, and right fusiform gyrus (Hart et al., ). In addition to decreased frontal–striatal connectivity, altered frontal–parietal connectivity may also play a role in the response inhibition impairment of ADHD (Cubillo et al., ).

Pharmacological studies show that administration of methylphenidate and atomoxetine improve action cancelation (Aron et al.,; Chamberlain et al.,; DeVito et al.,; Coghill et al., ) and action withholding (Vaidya et al., ) in ADHD patients, thereby suggesting that deficits in dopamine and noradrenalin underlie motor response inhibition deficits. Furthermore, use of methylphenidate increased prefrontal and striatal activation during performance of a Go/No Go task in ADHD patients (Vaidya et al., ). Methylphenidate also normalizes activation deficits in prefrontal, parietal, temporal, and cerebellar regions during performance of the Stop-signal task (Rubia et al., ). When effects of atomoxetine and methylphenidate were directly compared, both medications normalized left prefrontal underactivation during performance of the stop-signal task, while normalization of the right prefrontal activation was specific to use of methylphenidate (Cubillo et al., ).

Several candidate gene studies report on an association between genotype and response inhibition deficits in ADHD. In patients with ADHD, a polymorphism of the DRD4 gene, which is associated with decreased functional activity of the dopamine D4-receptor (Asghari et al., ), was related to altered performance on tasks with an inhibitory component (Langley et al.,; Bellgrove et al., ), impaired performance on the Stroop task (Loo et al., ), and reduced prefrontal cortical thickness (Shaw et al., ).

Attention-deficit hyperactivity disorder patients homozygous for a polymorphism of the DaT gene associated with increased transporter expression (Brookes et al., ), showed increased frontal and parietal brain activation during a modulated Go/no-go task (Braet et al., ), and showed increased activation in the striatum, premotor, and parietal cortices during inhibition in the Go/No-go task (Bedard et al., ). In contrast, a second study found increased striatal activity during inhibition in polymorphisms that result in decreased function (Durston et al., ).

In individuals with a specific polymorphism of the MAO-A gene, associated with lower levels of MAO-A, ADHD symptoms were related to decreased IFG activation during the Stop-signal task (Nymberg et al., ). MAO-A genotype of ADHD patients was not related to interference inhibition (Liu et al., ).

In summary, behavioral deficits in interference control and motor response inhibition are prominent in ADHD and associated with decreased volume and hypoactivation of CSTC areas. Results of gene-association studies suggest that reduced inhibitory performance may be related to decreased dopamine transmission in CSTC circuits.

Comparison between and Integration Across Disorders

All discussed disorders exhibit symptoms that signify a failure to inhibit certain impulses or responses. Response inhibition tasks therefore provide a very good operationalization to study the neural correlates of some dysfunctions contributing to the symptomatology of these disorders. From the above reviewed literature we can conclude that, overall, patients with obsessive–compulsive or related disorders exhibit deficits in response inhibition concomitant with alterations in the task-related brain activity. Whether these brain areas are hypo- or hyperactivated compared with matched healthy controls depends largely on the complexity of the task. In general, we can state that patients compensate behavior by recruiting additional inhibition-related brain areas, explaining why behavioral performance is often normal, but only during less complex tasks (e.g., the Flanker task and the Simon task). With increasing task demand (e.g., the Go/no-go and the Stop-signal task), these compensational mechanisms fail and patients start to show behavioral impairments and decreased inhibition-related neural circuit activity. This phenomenon has also been observed in healthy subjects (Sebastian et al., ), although they can “endure” tasks with higher demands before overstressing the inhibition network and concomitant decrements in performance. In other words, patients exhibit performance impairments and failure of compensatory activation at a lower task load than healthy controls. This has also been observed in OCD patients and their siblings and adult patients with ADHD while performing a working memory task such as the N-Back (de Vries et al.,; Ko et al., ). Figure 2 illustrates this as a shift to the left of an inverse U-shape relation between task load and inhibition-related activity. This shift in compensatory abilities does not have to be specific for the discussed disorders but may also apply to others, such Parkinson’s disease (Vriend et al., under review) or even natural aging (Sebastian et al., ).

The actual neurobiological mechanism for this shift is, unfortunately, less apparent and may involve (interactions between) electrophysiological anomalies, neurotransmitter dysfunction, genetic variance, etc. A prime candidate for the cause of the shift might by dysfunction of dopamine signaling. Dopamine is the major neuromodulator in the CSTC circuits and can either facilitate or inhibit their activation depending on the activation of their different receptor subtypes and dopamine concentrations (Alexander et al.,; Vriend et al., ).

As reviewed above, the CSTC circuits seem to be important for response inhibition (Aron, ) and are also involved in the pathophysiology underlying the dysfunctions related to the symptomatology of the obsessive–compulsive and related disorders. Whether or not dopamine is primarily involved in the pathophysiology of these disorders is still under debate, with some of the above reviewed studies showing clear associations, while others do not. Nevertheless, current evidence suggests that ADHD can be seen as a hypodopaminergic disorder, whereas OCD, TTM, and TS can be regarded as hyperdopaminergic disorders (Buse et al., ). This is also consistent with the currently available pharmacological treatments, whose neurobiological mechanism is thought to rely on restoring dopamine to physiological levels (Abi-Dargham and Laruelle,; Gerlach et al., ). Even SSRI’s and tricyclic antidepressants, the first line pharmacological treatment of OCD, may normalize dopamine levels by upregulation of serotonin signaling, that has an inhibitory effect on dopamine (Boureau and Dayan, ). Figure 3 provides a schematic representation of the proposed relation between dopamine levels and inhibitory control. This relation is similar to the inverse U-shaped relation proposed for dopamine levels and working memory function (Cools and D’Esposito, ).

The proposed relation obviously does not provide the full story and is merely intended as a framework to understand some of the findings discussed in this review. Dopamine has differential effects in the prefrontal cortex and striatum, different firing modes (i.e., tonic and phasic) and highly complex interactions with other neurotransmitter systems, including the serotonin, noradrenalin, and glutamate system, and even hormones, such as estrogens (Boureau and Dayan,; Cools and D’Esposito,; de Bartolomeis et al., ), which prohibits a clear understanding of the influence of these neurotransmitters on brain activity and behavior.

In short, the functional and behavioral deficits in response inhibition in obsessive–compulsive and related disorders can be conceptualized as a shift in the relation between task demands and inhibition-related neural circuit activity. What causes this shift and what could thereby underlie the symptoms of these disorders is currently unknown, although we postulate that dopamine plays a critical role.

Conclusion and Future Directions

The aim of this review was to provide an overview of the studies that examined the neural, pharmacological, and genetic substrates of inhibitory impairment of disorders within the impulsive–compulsive spectrum, with a focus on OCD, ADHD, TS, and TTM. We have shown that functionally and behaviorally impaired response inhibition is a shared characteristic among these disorders and may underlie at least some of the dysfunctions related to the symptomatology of the disorders. Neuroimaging studies suggest that inhibition-related brain areas are mostly hypoactivated in ADHD and OCD (although dependent on the task load), while studies in TS have provided mixed results. To our knowledge, no study has yet been published on the neural correlates of response inhibition in TTM. Dopamine and serotonin signaling seems to be important for response inhibition and dysfunction of these neurotransmitters has been frequently observed in the obsessive–compulsive and related disorders. Nevertheless, almost all imaging studies on neurotransmitters have been performed in patients that received (chronic) pharmacotherapy, which may have influenced the scan directly, due to competition of the drug with a radioligand for a specific binding site, or indirectly because the brain adapts to the pharmacological effects (Wang et al., ). For a better understanding of the pathophysiology of the disease itself and the identification of novel treatment targets, more studies are needed in medication-naïve patients. Prospective follow-up of these patients after commencing treatment can subsequently provide insights into the effect of treatment on response inhibition impairments and its relation to disorder-specific symptoms. Lastly, there is a relative lack of studies that compare the pathophysiology of inhibitory deficits across related mental disorders. Such studies allow the identification of common as well as specific disease biomarkers of impulsivity and compulsivity symptoms.

Author Contributions

All authors were involved in design of this review; Laura S. van Velzen and Chris Vriend drafted the first version of the manuscript; all authors contributed to the interpretation of the literature, revised earlier drafts of this article and have approved the final version of the manuscript and its submission.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References 220

  1. 1.

    Abi-Dargham A. Laruelle M. (2005 ). Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. Eur. Psychiatry 20, 15–27

    Not in our library10.1016/j.eurpsy.2004.11.003

  2. 2.

    Albin R. L. Mink J. W. (2006 ). Recent advances in Tourette syndrome research. Trends Neurosci. 29, 175–182

    Not in our library10.1016/j.tins.2006.01.001

  3. 3.

    Alderson R. M. Rapport M. D. Kofler M. J. (2007 ). Attention-deficit/hyperactivity disorder and behavioral inhibition: a meta-analytic review of the stop-signal paradigm. J. Abnorm. Child Psychol. 35, 745–758

    Not in our library10.1007/s10802-007-9131-6

  4. 4.

    Alexander G. E. DeLong M. R. Strick P. L. (1986 ). Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu. Rev. Neurosci. 9, 357–381

    Not in our library10.1146/annurev.ne.09.030186.002041

  5. 5.

    American Psychiatric Association. (2013 ). Diagnostic and Statistical Manual of Mental Disorders. 5th Edn, Arlington: American Psychiatric Publishing

    Not in our library

  6. 6.

    Anderson I. M. Clark L. Elliott R. Kulkarni B. Williams S. R. Deakin J. F. (2002 ). 5-HT(2C) receptor activation by m-chlorophenylpiperazine detected in humans with fMRI. Neuroreport 13, 1547–1551

    Not in our library10.1097/00001756-200208270-00012

  7. 7.

    Aron A. R. (2011 ). From reactive to proactive and selective control: developing a richer model for stopping inappropriate responses. Biol. Psychiatry 69, e55–e68

    Not in our library10.1016/j.biopsych.2010.07.024

  8. 8.

    Aron A. R. Dowson J. H. Sahakian B. J. Robbins T. W. (2003a ). Methylphenidate improves response inhibition in adults with attention-deficit/hyperactivity disorder. Biol. Psychiatry 54, 1465–1468

    Not in our library10.1016/s0006-3223(03)00609-7

  9. 9.

    Aron A. R. Fletcher P. C. Bullmore E. T. Sahakian B. J. Robbins T. W. (2003b ). Stop-signal inhibition disrupted by damage to right inferior frontal gyrus in humans. Nat. Neurosci. 6, 115–116

    Not in our library10.1038/nn1003

  10. 10.

    Asghari V. Sanyal S. Buchwaldt S. Paterson A. Jovanovic V. Van Tol H. H. (1995 ). Modulation of intracellular cyclic AMP levels by different human dopamine D4 receptor variants. J. Neurochem. 65, 1157–1165

    Not in our library10.1046/j.1471-4159.1995.65031157.x

  11. 11.

    Baehne C. G. Ehlis A. C. Plichta M. M. Conzelmann A. Pauli P. Jacob C. (2009 ). TPH2 gene variants modulate response control processes in adult ADHD patients and healthy individuals. Mol. Psychiatry 14, 1032–1039

    Not in our library10.1038/mp.2008.39

  12. 12.

    Banich M. T. Burgess G. C. Depue B. E. Ruzic L. Bidwell L. C. Hitt-Laustsen S. (2009 ). The neural basis of sustained and transient attentional control in young adults with ADHD. Neuropsychologia 47, 3095–3104

    Not in our library10.1016/j.neuropsychologia.2009.07.005

  13. 13.

    Bannon S. Gonsalvez C. J. Croft R. J. Boyce P. M. (2002 ). Response inhibition deficits in obsessive-compulsive disorder. Psychiatry Res. 110, 165–174

    Not in our library10.1016/s0165-1781(02)00104-x

  14. 14.

    Bari A. Eagle D. M. Mar A. C. Robinson E. S. Robbins T. W. (2009 ). Dissociable effects of noradrenaline, dopamine, and serotonin uptake blockade on stop task performance in rats. Psychopharmacology (Berl.) 205, 273–283

    Not in our library10.1007/s00213-009-1537-0

  15. 15.

    Bari A. Robbins T. W. (2013 ). Inhibition and impulsivity: behavioral and neural basis of response control. Prog. Neurobiol. 108, 44–79

    Not in our library10.1016/j.pneurobio.2013.06.005

  16. 16.

    Baron-Cohen S. Cross P. Crowson M. Robertson M. (1994 ). Can children with Gilles de la Tourette syndrome edit their intentions? Psychol. Med. 24, 29–40

    Not in our library10.1017/s0033291700026805

  17. 17.
    Cortical Gray Matter in Attention-Deficit/Hyperactivity Disorder: A Structural Magnetic Resonance Imaging Study · 2010
    No notice
  18. 18.

    Bedard A. C. Schulz K. P. Cook E. H. Jr. Fan J. Clerkin S. M. Ivanov I. (2010 ). Dopamine transporter gene variation modulates activation of striatum in youth with ADHD. Neuroimage 53, 935–942

    Not in our library10.1016/j.neuroimage.2009.12.041

  19. 19.

    Bellgrove M. A. Hawi Z. Lowe N. Kirley A. Robertson I. H. Gill M. (2005 ). DRD4 gene variants and sustained attention in attention deficit hyperactivity disorder (ADHD): effects of associated alleles at the VNTR and -521 SNP. Am. J. Med. Genet. B Neuropsychiatr. Genet. 136B, 81–86

    Not in our library10.1002/ajmg.b.30193

  20. 20.

    Blasi G. Goldberg T. E. Weickert T. Das S. Kohn P. Zoltick B. (2006 ). Brain regions underlying response inhibition and interference monitoring and suppression. Eur. J. Neurosci. 23, 1658–1664

    Not in our library10.1111/j.1460-9568.2006.04680.x

  21. 21.

    Bloch M. State M. Pittenger C. (2011 ). Recent advances in Tourette syndrome. Curr. Opin. Neurol. 24, 119–125

    Not in our library10.1097/wco.0b013e328344648c

  22. 22.

    Bohne A. Keuthen N. J. Tuschen-Caffier B. Wilhelm S. (2005 ). Cognitive inhibition in trichotillomania and obsessive-compulsive disorder. Behav. Res. Ther. 43, 923–942

    Not in our library10.1016/j.brat.2004.06.014

  23. 23.

    Bohne A. Savage C. R. Deckersbach T. Keuthen N. J. Wilhelm S. (2008 ). Motor inhibition in trichotillomania and obsessive-compulsive disorder. J. Psychiatr. Res. 42, 141–150

    Not in our library10.1016/j.jpsychires.2006.11.008

  24. 24.

    Booth J. R. Burman D. D. Meyer J. R. Lei Z. Trommer B. L. Davenport N. D. (2005 ). Larger deficits in brain networks for response inhibition than for visual selective attention in attention deficit hyperactivity disorder (ADHD). J. Child Psychol. Psychiatry 46, 94–111

    Not in our library10.1111/j.1469-7610.2004.00337.x

  25. 25.

    Boureau Y.-L. Dayan P. (2010 ). Opponency revisited: competition and cooperation between dopamine and serotonin. Neuropsychopharmacology 36, 74–97

    Not in our library10.1038/npp.2010.151

  26. 26.

    Braet W. Johnson K. A. Tobin C. T. Acheson R. McDonnell C. Hawi Z. (2011 ). fMRI activation during response inhibition and error processing: the role of the DAT1 gene in typically developing adolescents and those diagnosed with ADHD. Neuropsychologia 49, 1641–1650

    Not in our library10.1016/j.neuropsychologia.2011.01.001

  27. 27.

    Brookes K. J. Neale B. M. Sugden K. Khan N. Asherson P. D’Souza U. M. (2007 ). Relationship between VNTR polymorphisms of the human dopamine transporter gene and expression in post-mortem midbrain tissue. Am. J. Med. Genet. B Neuropsychiatr. Genet. 144B, 1070–1078

    Not in our library10.1002/ajmg.b.30572

  28. 28.

    Burgess G. C. Depue B. E. Ruzic L. Willcutt E. G. Du Y. P. Banich M. T. (2010 ). Attentional control activation relates to working memory in attention-deficit/hyperactivity disorder. Biol. Psychiatry 67, 632–640

    Not in our library10.1016/j.biopsych.2009.10.036

  29. 29.

    Buse J. Schoenefeld K. Munchau A. Roessner V. (2013 ). Neuromodulation in Tourette syndrome: dopamine and beyond. Neurosci. Biobehav. Rev. 37, 1069–1084

    Not in our library10.1016/j.neubiorev.2012.10.004

  30. 30.

    Bush G. Frazier J. A. Rauch S. L. Seidman L. J. Whalen P. J. Jenike M. A. (1999 ). Anterior cingulate cortex dysfunction in attention-deficit/hyperactivity disorder revealed by fMRI and the counting Stroop. Biol. Psychiatry 45, 1542–1552

    Not in our library10.1016/s0006-3223(99)00083-9

  31. 31.

    Cai W. George J. S. Verbruggen F. Chambers C. D. Aron A. R. (2012 ). The role of the right presupplementary motor area in stopping action: two studies with event-related transcranial magnetic stimulation. J. Neurophysiol. 108, 380–389

    Not in our library10.1152/jn.00132.2012

  32. 32.

    Casey B. J. Castellanos F. X. Giedd J. N. Marsh W. L. Hamburger S. D. Schubert A. B. (1997 ). Implication of right frontostriatal circuitry in response inhibition and attention-deficit/hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry 36, 374–383

    Not in our library10.1097/00004583-199703000-00016

  33. 33.

    Chamberlain S. R. Blackwell A. D. Fineberg N. A. Robbins T. W. Sahakian B. J. (2005 ). The neuropsychology of obsessive compulsive disorder: the importance of failures in cognitive and behavioural inhibition as candidate endophenotypic markers. Neurosci. Biobehav. Rev. 29, 399–419

    Not in our library10.1016/j.neubiorev.2004.11.006

  34. 34.

    Chamberlain S. R. Del Campo N. Dowson J. Muller U. Clark L. Robbins T. W. (2007a ). Atomoxetine improved response inhibition in adults with attention deficit/hyperactivity disorder. Biol. Psychiatry 62, 977–984

    Not in our library10.1016/j.biopsych.2007.03.003

  35. 35.

    Chamberlain S. R. Fineberg N. A. Blackwell A. D. Robbins T. W. Sahakian B. J. (2006a ). Motor inhibition and cognitive flexibility in obsessive-compulsive disorder and trichotillomania. Am. J. Psychiatry 163, 1282–1284

    Not in our library10.1176/appi.ajp.163.7.1282

  36. 36.

    Chamberlain S. R. Fineberg N. A. Menzies L. A. Blackwell A. D. Bullmore E. T. Robbins T. W. (2007b ). Impaired cognitive flexibility and motor inhibition in unaffected first-degree relatives of patients with obsessive-compulsive disorder. Am. J. Psychiatry 164, 335–338

    Not in our library10.1176/appi.ajp.164.2.335

  37. 37.

    Chamberlain S. R. Menzies L. A. Fineberg N. A. Del Campo N. Suckling J. Craig K. (2008 ). Grey matter abnormalities in trichotillomania: morphometric magnetic resonance imaging study. Br. J. Psychiatry 193, 216–221

    Not in our library10.1192/bjp.bp.107.048314

  38. 38.

    Chamberlain S. R. Muller U. Blackwell A. D. Clark L. Robbins T. W. Sahakian B. J. (2006b ). Neurochemical modulation of response inhibition and probabilistic learning in humans. Science 311, 861–863

    Not in our library10.1126/science.1121218

  39. 39.

    Chambers C. D. Bellgrove M. A. Stokes M. G. Henderson T. R. Garavan H. Robertson I. H. (2006 ). Executive “brake failure” following deactivation of human frontal lobe. J. Cogn. Neurosci. 18, 444–455

    Not in our library10.1162/089892906775990606

  40. 40.

    Chambers C. D. Garavan H. Bellgrove M. A. (2009 ). Insights into the neural basis of response inhibition from cognitive and clinical neuroscience. Neurosci. Biobehav. Rev. 33, 631–646

    Not in our library10.1016/j.neubiorev.2008.08.016

  41. 41.

    Channon S. Drury H. Martinos M. Robertson M. M. Orth M. Crawford S. (2009 ). Tourette’s syndrome (TS): inhibitory performance in adults with uncomplicated TS. Neuropsychology 23, 359–366

    Not in our library10.1037/a0014552

  42. 42.

    Channon S. Gunning A. Frankl J. Robertson M. M. (2006 ). Tourette’s syndrome (TS): cognitive performance in adults with uncomplicated TS. Neuropsychology 20, 58–65

    Not in our library10.1037/0894-4105.20.1.58

  43. 43.

    Chen J. Lipska B. K. Halim N. Ma Q. D. Matsumoto M. Melhem S. (2004 ). Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am. J. Hum. Genet. 75, 807–821

    Not in our library10.1086/425589

  44. 44.

    Cheon K. A. Ryu Y. H. Namkoong K. Kim C. H. Kim J. J. Lee J. D. (2004 ). Dopamine transporter density of the basal ganglia assessed with [123I]IPT SPECT in drug-naive children with Tourette’s disorder. Psychiatry Res. 130, 85–95

    Not in our library10.1016/j.pscychresns.2003.06.001

  45. 45.

    Clark L. Roiser J. P. Cools R. Rubinsztein D. C. Sahakian B. J. Robbins T. W. (2005 ). Stop signal response inhibition is not modulated by tryptophan depletion or the serotonin transporter polymorphism in healthy volunteers: implications for the 5-HT theory of impulsivity. Psychopharmacology (Berl.) 182, 570–578

    Not in our library10.1007/s00213-005-0104-6

  46. 46.

    Coghill D. R. Seth S. Pedroso S. Usala T. Currie J. Gagliano A. (2013 ). Effects of methylphenidate on cognitive functions in children and adolescents with attention-deficit/hyperactivity disorder: evidence from a systematic review and a meta-analysis. Biol. Psychiatry.

    Not in our library10.1016/j.biopsych.2013.10.005

  47. 47.

    Colzato L. S. van den Wildenberg W. P. Van der Does A. J. Hommel B. (2010 ). Genetic markers of striatal dopamine predict individual differences in dysfunctional, but not functional impulsivity. Neuroscience 170, 782–788

    Not in our library10.1016/j.neuroscience.2010.07.050

  48. 48.

    Congdon E. Constable R. T. Lesch K. P. Canli T. (2009 ). Influence of SLC6A3 and COMT variation on neural activation during response inhibition. Biol. Psychol. 81, 144–152

    Not in our library10.1016/j.biopsycho.2009.03.005

  49. 49.

    Congdon E. Lesch K. P. Canli T. (2008 ). Analysis of DRD4 and DAT polymorphisms and behavioral inhibition in healthy adults: implications for impulsivity. Am. J. Med. Genet. B Neuropsychiatr. Genet. 147B, 27–32

    Not in our library10.1002/ajmg.b.30557

  50. 50.

    Cools R. D’Esposito M. (2011 ). Inverted-U-shaped dopamine actions on human working memory and cognitive control. Biol. Psychiatry 69, e113–e125

    Not in our library10.1016/j.biopsych.2011.03.028

  51. 51.

    Cornish K. M. Manly T. Savage R. Swanson J. Morisano D. Butler N. (2005 ). Association of the dopamine transporter (DAT1) 10/10-repeat genotype with ADHD symptoms and response inhibition in a general population sample. Mol. Psychiatry 10, 686–698

    Not in our library10.1038/sj.mp.4001641

  52. 52.

    Crawford S. Channon S. Robertson M. M. (2005 ). Tourette’s syndrome: performance on tests of behavioural inhibition, working memory and gambling. J. Child Psychol. Psychiatry 46, 1327–1336

    Not in our library10.1111/j.1469-7610.2005.01419.x

  53. 53.

    Cubillo A. Halari R. Ecker C. Giampietro V. Taylor E. Rubia K. (2010 ). Reduced activation and inter-regional functional connectivity of fronto-striatal networks in adults with childhood attention-deficit hyperactivity disorder (ADHD) and persisting symptoms during tasks of motor inhibition and cognitive switching. J. Psychiatr. Res. 44, 629–639

    Not in our library10.1016/j.jpsychires.2009.11.016

  54. 54.

    Cubillo A. Halari R. Giampietro V. Taylor E. Rubia K. (2011 ). Fronto-striatal underactivation during interference inhibition and attention allocation in grown up children with attention deficit/hyperactivity disorder and persistent symptoms. Psychiatry Res. 193, 17–27

    Not in our library10.1016/j.pscychresns.2010.12.014

  55. 55.

    Cubillo A. Smith A. B. Barrett N. Giampietro V. Brammer M. J. Simmons A. (2014 ). Shared and drug-specific effects of atomoxetine and methylphenidate on inhibitory brain dysfunction in medication-naive ADHD boys. Cereb. Cortex 24, 174–185

    Not in our library10.1093/cercor/bhs296

  56. 56.

    Cummins T. D. Hawi Z. Hocking J. Strudwick M. Hester R. Garavan H. (2012 ). Dopamine transporter genotype predicts behavioural and neural measures of response inhibition. Mol. Psychiatry 17, 1086–1092

    Not in our library10.1038/mp.2011.104

  57. 57.

    Dalley J. W. Roiser J. P. (2012 ). Dopamine, serotonin and impulsivity. Neuroscience 215, 42–58

    Not in our library10.1016/j.neuroscience.2012.03.065

  58. 58.

    de Bartolomeis A. Buonaguro E. Iasevoli F. (2013 ). Serotonin-glutamate and serotonin-dopamine reciprocal interactions as putative molecular targets for novel antipsychotic treatments: from receptor heterodimers to postsynaptic scaffolding and effector proteins. Psychopharmacology 225, 1–19

    Not in our library10.1007/s00213-012-2921-8

  59. 59.

    de Vries F. E. de Wit S. J. Cath D. C. van der Werf Y. D. van der Borden V. van Rossum T. B. (2013 ). Compensatory frontoparietal activity during working memory: an endophenotype of obsessive-compulsive disorder. Biol. Psychiatry.

    Not in our library10.1016/j.biopsych.2013.11.021

  60. 60.

    de Wit S. J. de Vries F. E. van der Werf Y. D. Cath D. C. Heslenfeld D. J. Veltman E. M. (2012 ). Presupplementary motor area hyperactivity during response inhibition: a candidate endophenotype of obsessive-compulsive disorder. Am. J. Psychiatry 169, 1100–1108

    Not in our library10.1176/appi.ajp.2012.12010073

  61. 61.

    Denys D. de Geus F. van Megen H. J. Westenberg H. G. (2004a ). A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. J. Clin. Psychiatry 65, 1040–1048

    Not in our library10.4088/jcp.v65n0803

  62. 62.

    Denys D. van der Wee N. Janssen J. De Geus F. Westenberg H. G. (2004b ). Low level of dopaminergic D2 receptor binding in obsessive-compulsive disorder. Biol. Psychiatry 55, 1041–1045

    Not in our library10.1016/j.biopsych.2004.01.023

  63. 63.

    Depue B. E. Burgess G. C. Bidwell L. C. Willcutt E. G. Banich M. T. (2010 ). Behavioral performance predicts grey matter reductions in the right inferior frontal gyrus in young adults with combined type ADHD. Psychiatry Res. 182, 231–237

    Not in our library10.1016/j.pscychresns.2010.01.012

  64. 64.

    DeVito E. E. Blackwell A. D. Clark L. Kent L. Dezsery A. M. Turner D. C. (2009 ). Methylphenidate improves response inhibition but not reflection-impulsivity in children with attention deficit hyperactivity disorder (ADHD). Psychopharmacology (Berl.) 202, 531–539

    Not in our library10.1007/s00213-008-1337-y

  65. 65.

    DeVito T. J. Drost D. J. Pavlosky W. Neufeld R. W. Rajakumar N. McKinlay B. D. (2005 ). Brain magnetic resonance spectroscopy in Tourette’s disorder. J. Am. Acad. Child Adolesc. Psychiatry 44, 1301–1308

    Not in our library10.1097/01.chi.0000181046.52078.f4

  66. 66.

    Dibbets P. Evers L. Hurks P. Marchetta N. Jolles J. (2009 ). Differences in feedback- and inhibition-related neural activity in adult ADHD. Brain Cogn. 70, 73–83

    Not in our library10.1016/j.bandc.2009.01.001

  67. 67.

    Dillo W. Goke A. Prox-Vagedes V. Szycik G. R. Roy M. Donnerstag F. (2010 ). Neuronal correlates of ADHD in adults with evidence for compensation strategies – a functional MRI study with a Go/No-Go paradigm. Ger. Med. Sci. 8, Doc09

    Not in our library10.3205/000098

  68. 68.

    Donders F. C. (1969 ). On the speed of mental processes. Acta Psychol. 30, 412–431 [Originally published in Dutch, translated by W. G. Koster]

    Not in our library10.1016/0001-6918(69)90065-1

  69. 69.

    Draganski B. Martino D. Cavanna A. E. Hutton C. Orth M. Robertson M. M. (2010 ). Multispectral brain morphometry in Tourette syndrome persisting into adulthood. Brain 133(Pt 12), 3661–3675

    Not in our library10.1093/brain/awq300

  70. 70.

    Drueke B. Boecker M. Schlaegel S. Moeller O. Hiemke C. Grunder G. (2010 ). Serotonergic modulation of response inhibition and re-engagement? Results of a study in healthy human volunteers. Hum. Psychopharmacol. 25, 472–480

    Not in our library10.1002/hup.1141

  71. 71.

    Durston S. (2003 ). A review of the biological bases of ADHD: what have we learned from imaging studies? Ment. Retard. Dev. Disabil. Res. Rev. 9, 184–195

    Not in our library10.1002/mrdd.10079

  72. 72.

    Durston S. Fossella J. A. Mulder M. J. Casey B. J. Ziermans T. B. Vessaz M. N. (2008 ). Dopamine transporter genotype conveys familial risk of attention-deficit/hyperactivity disorder through striatal activation. J. Am. Acad. Child Adolesc. Psychiatry 47, 61–67

    Not in our library10.1097/chi.0b013e31815a5f17

  73. 73.

    Durston S. Tottenham N. T. Thomas K. M. Davidson M. C. Eigsti I. M. Yang Y. (2003 ). Differential patterns of striatal activation in young children with and without ADHD. Biol. Psychiatry 53, 871–878

    Not in our library10.1016/s0006-3223(02)01904-2

  74. 74.

    Eagle D. M. Bari A. Robbins T. W. (2008 ). The neuropsychopharmacology of action inhibition: cross-species translation of the stop-signal and go/no-go tasks. Psychopharmacology (Berl.) 199, 439–456

    Not in our library10.1007/s00213-008-1127-6

  75. 75.

    Eagle D. M. Lehmann O. Theobald D. E. Pena Y. Zakaria R. Ghosh R. (2009 ). Serotonin depletion impairs waiting but not stop-signal reaction time in rats: implications for theories of the role of 5-HT in behavioral inhibition. Neuropsychopharmacology 34, 1311–1321

    Not in our library10.1038/npp.2008.202

  76. 76.

    Eagle D. M. Tufft M. R. Goodchild H. L. Robbins T. W. (2007 ). Differential effects of modafinil and methylphenidate on stop-signal reaction time task performance in the rat, and interactions with the dopamine receptor antagonist cis-flupenthixol. Psychopharmacology (Berl.) 192, 193–206

    Not in our library10.1007/s00213-007-0701-7

  77. 77.

    Eichele H. Eichele T. Hammar A. Freyberger H. J. Hugdahl K. Plessen K. J. (2010 ). Go/NoGo performance in boys with Tourette syndrome. Child Neuropsychol. 16, 162–168

    Not in our library10.1080/09297040903150182

  78. 78.

    Evers E. A. van der Veen F. M. van Deursen J. A. Schmitt J. A. Deutz N. E. Jolles J. (2006 ). The effect of acute tryptophan depletion on the BOLD response during performance monitoring and response inhibition in healthy male volunteers. Psychopharmacology (Berl.) 187, 200–208

    Not in our library10.1007/s00213-006-0411-6

  79. 79.

    Felling R. J. Singer H. S. (2011 ). Neurobiology of Tourette syndrome: current status and need for further investigation. J. Neurosci. 31, 12387–12395

    Not in our library10.1523/jneurosci.0150-11.2011

  80. 80.

    Fineberg N. A. Sivakumaran T. Roberts A. Gale T. (2005 ). Adding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder: a randomized controlled treatment study. Int. Clin. Psychopharmacol. 20, 223–226

    Not in our library10.1097/00004850-200507000-00005

  81. 81.

    Fitzgerald K. D. Welsh R. C. Gehring W. J. Abelson J. L. Himle J. A. Liberzon I. (2005 ). Error-related hyperactivity of the anterior cingulate cortex in obsessive-compulsive disorder. Biol. Psychiatry 57, 287–294

    Not in our library10.1016/j.biopsych.2004.10.038

  82. 82.

    Floden D. Stuss D. T. (2006 ). Inhibitory control is slowed in patients with right superior medial frontal damage. J. Cogn. Neurosci. 18, 1843–1849

    Not in our library10.1162/jocn.2006.18.11.1843

  83. 83.

    Frodl T. Skokauskas N. (2012 ). Meta-analysis of structural MRI studies in children and adults with attention deficit hyperactivity disorder indicates treatment effects. Acta Psychiatr. Scand. 125, 114–126

    Not in our library10.1111/j.1600-0447.2011.01786.x

  84. 84.

    Froehlich T. E. Lanphear B. P. Epstein J. N. Barbaresi W. J. Katusic S. K. Kahn R. S. (2007 ). Prevalence, recognition, and treatment of attention-deficit/hyperactivity disorder in a national sample of US children. Arch. Pediatr. Adolesc. Med. 161, 857–864

    Not in our library10.1001/archpedi.161.9.857

  85. 85.

    Gadde K. M. Ryan Wagner H. II Connor K. M. Foust M. S. (2007 ). Escitalopram treatment of trichotillomania. Int. Clin. Psychopharmacol. 22, 39–42

    Not in our library10.1097/01.yic.0000224799.59524.50

  86. 86.

    Gerlach M. Grunblatt E. Lange K. W. (2013 ). Is the treatment with psychostimulants in children and adolescents with attention deficit hyperactivity disorder harmful for the dopaminergic system? Atten. Defic. Hyperact. Disord. 5, 71–81

    Not in our library10.1007/s12402-013-0105-y

  87. 87.

    Ghahremani D. G. Lee B. Robertson C. L. Tabibnia G. Morgan A. T. De Shetler N. (2012 ). Striatal dopamine D(2)/D(3) receptors mediate response inhibition and related activity in frontostriatal neural circuitry in humans. J. Neurosci. 32, 7316–7324

    Not in our library10.1523/jneurosci.4284-11.2012

  88. 88.

    Ghanizadeh A. Mosallaei S. (2009 ). Psychiatric disorders and behavioral problems in children and adolescents with Tourette syndrome. Brain Dev. 31, 15–19

    Not in our library10.1016/j.braindev.2008.03.010

  89. 89.

    Gilbert D. L. Christian B. T. Gelfand M. J. Shi B. Mantil J. Sallee F. R. (2006 ). Altered mesolimbocortical and thalamic dopamine in Tourette syndrome. Neurology 67, 1695–1697

    Not in our library10.1212/01.wnl.0000242733.18534.2c

  90. 90.

    Gottesman I. I. Gould T. D. (2003 ). The endophenotype concept in psychiatry: etymology and strategic intentions. Am. J. Psychiatry 160, 636–645

    Not in our library10.1176/appi.ajp.160.4.636

  91. 91.

    Grachev I. D. (1997 ). MRI-based morphometric topographic parcellation of human neocortex in trichotillomania. Psychiatry Clin. Neurosci. 51, 315–321

    Not in our library10.1111/j.1440-1819.1997.tb03205.x

  92. 92.

    Hart H. Radua J. Nakao T. Mataix-Cols D. Rubia K. (2012 ). Meta-analysis of functional magnetic resonance imaging studies of inhibition and attention in attention-deficit/hyperactivity disorder: exploring task-specific, stimulant medication, and age effects. Arch. Gen. Psychiatry 70, 1–14

    Not in our library10.1001/jamapsychiatry.2013.277

  93. 93.

    Haugbol S. Pinborg L. H. Regeur L. Hansen E. S. Bolwig T. G. Nielsen F. A. (2007 ). Cerebral 5-HT2A receptor binding is increased in patients with Tourette’s syndrome. Int. J. Neuropsychopharmacol. 10, 245–252

    Not in our library10.1017/s1461145706006559

  94. 94.

    Hershey T. Black K. J. Hartlein J. Braver T. S. Barch D. M. Carl J. L. (2004 ). Dopaminergic modulation of response inhibition: an fMRI study. Brain Res. Cogn. Brain Res. 20, 438–448

    Not in our library10.1016/j.cogbrainres.2004.03.018

  95. 95.

    Hesse S. Muller U. Lincke T. Barthel H. Villmann T. Angermeyer M. C. (2005 ). Serotonin and dopamine transporter imaging in patients with obsessive-compulsive disorder. Psychiatry Res. 140, 63–72

    Not in our library10.1016/j.pscychresns.2005.07.002

  96. 96.

    Hirvonen M. M. Laakso A. Nagren K. Rinne J. O. Pohjalainen T. Hietala J. (2009 ). C957T polymorphism of dopamine D2 receptor gene affects striatal DRD2 in vivo availability by changing the receptor affinity. Synapse 63, 907–912

    Not in our library10.1002/syn.20672

  97. 97.

    Holmes A. J. Bogdan R. Pizzagalli D. A. (2010 ). Serotonin transporter genotype and action monitoring dysfunction: a possible substrate underlying increased vulnerability to depression. Neuropsychopharmacology 35, 1186–1197

    Not in our library10.1038/npp.2009.223

  98. 98.

    Horacek J. Zavesicka L. Tintera J. Dockery C. Platilova V. Kopecek M. (2005 ). The effect of tryptophan depletion on brain activation measured by functional magnetic resonance imaging during the Stroop test in healthy subjects. Physiol. Res. 54, 235–244

    Not in our library

  99. 99.

    Huster R. J. Enriquez-Geppert S. Lavallee C. F. Falkenstein M. Herrmann C. S. (2013 ). Electroencephalography of response inhibition tasks: functional networks and cognitive contributions. Int. J. Psychophysiol. 87, 217–233

    Not in our library10.1016/j.ijpsycho.2012.08.001

  100. 100.

    Huyser C. Veltman D. J. Wolters L. H. de Haan E. Boer F. (2011 ). Developmental aspects of error and high-conflict-related brain activity in pediatric obsessive-compulsive disorder: a fMRI study with a Flanker task before and after CBT. J. Child Psychol. Psychiatry 52, 1251–1260

    Not in our library10.1111/j.1469-7610.2011.02439.x

  101. 101.

    Hwang W. J. Yao W. J. Fu Y. K. Yang A. S. (2008 ). [99mTc]TRODAT-1/[123I]IBZM SPECT studies of the dopaminergic system in Tourette syndrome. Psychiatry Res. 162, 159–166

    Not in our library10.1016/j.pscychresns.2007.04.006

  102. 102.

    Johannes S. Wieringa B. M. Mantey M. Nager W. Rada D. Muller-Vahl K. R. (2001 ). Altered inhibition of motor responses in Tourette syndrome and obsessive-compulsive disorder. Acta Neurol. Scand. 104, 36–43

    Not in our library10.1034/j.1600-0404.2001.00308.x

  103. 103.

    Kang D. H. Jang J. H. Han J. Y. Kim J. H. Jung W. H. Choi J. S. (2012 ). Neural correlates of altered response inhibition and dysfunctional connectivity at rest in obsessive-compulsive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 40, 340–346

    Not in our library10.1016/j.pnpbp.2012.11.001

  104. 104.

    Kim C. H. Koo M. S. Cheon K. A. Ryu Y. H. Lee J. D. Lee H. S. (2003 ). Dopamine transporter density of basal ganglia assessed with [123I]IPT SPET in obsessive-compulsive disorder. Eur. J. Nucl. Med. Mol. Imaging 30, 1637–1643

    Not in our library10.1007/s00259-003-1245-7

  105. 105.

    Ko C.-H. Yen J.-Y. Yen C.-F. Chen C.-S. Lin W.-C. Wang P.-W. (2013 ). Brain activation deficit in increased-load working memory tasks among adults with ADHD using fMRI. Eur. Arch. Psychiatry Clin. Neurosci. 263, 1–13

    Not in our library10.1007/s00406-013-0407-2

  106. 106.

    Kooistra L. van der Meere J. J. Edwards J. D. Kaplan B. J. Crawford S. Goodyear B. G. (2010 ). Preliminary fMRI findings on the effects of event rate in adults with ADHD. J. Neural Transm. 117, 655–662

    Not in our library10.1007/s00702-010-0374-y

  107. 107.

    Kramer U. M. Cunillera T. Camara E. Marco-Pallares J. Cucurell D. Nager W. (2007 ). The impact of catechol-O-methyltransferase and dopamine D4 receptor genotypes on neurophysiological markers of performance monitoring. J. Neurosci. 27, 14190–14198

    Not in our library10.1523/jneurosci.4229-07.2007

  108. 108.

    Kramer U. M. Rojo N. Schule R. Cunillera T. Schols L. Marco-Pallares J. (2009 ). ADHD candidate gene (DRD4 exon III) affects inhibitory control in a healthy sample. BMC Neurosci. 10:150

    Not in our library10.1186/1471-2202-10-150

  109. 109.

    Langley K. Marshall L. van den Bree M. Thomas H. Owen M. O’Donovan M. (2004 ). Association of the dopamine D4 receptor gene 7-repeat allele with neuropsychological test performance of children with ADHD. Am. J. Psychiatry 161, 133–138

    Not in our library10.1176/appi.ajp.161.1.133

  110. 110.

    Lipszyc J. Schachar R. (2010 ). Inhibitory control and psychopathology: a meta-analysis of studies using the stop signal task. J. Int. Neuropsychol. Soc. 16, 1064–1076

    Not in our library10.1017/s1355617710000895

  111. 111.

    Liu H. Dong F. Meng Z. Zhang B. Tan J. Wang Y. (2010 ). Evaluation of Tourette’s syndrome by (99m)Tc-TRODAT-1 SPECT/CT imaging. Ann. Nucl. Med. 24, 515–521

    Not in our library10.1007/s12149-010-0389-3

  112. 112.

    Liu L. Guan L. L. Chen Y. Ji N. Li H. M. Li Z. H. (2011 ). Association analyses of MAOA in Chinese Han subjects with attention-deficit/hyperactivity disorder: family-based association test, case-control study, and quantitative traits of impulsivity. Am. J. Med. Genet. B Neuropsychiatr. Genet. 156B, 737–748

    Not in our library10.1002/ajmg.b.31217

  113. 113.

    Logan G. D. (1994 ). “On the ability to inhibit thought and action: a user’s guide to the stop signal paradigm,” in Inhibitory Processes in Attention, Memory and Language, eds Dagenbach D. Carr T. H. (San Diego, CA: Academic Press), 189–239

    Not in our library

  114. 114.

    Loo S. K. Rich E. C. Ishii J. McGough J. McCracken J. Nelson S. (2008 ). Cognitive functioning in affected sibling pairs with ADHD: familial clustering and dopamine genes. J. Child Psychol. Psychiatry 49, 950–957

    Not in our library10.1111/j.1469-7610.2008.01928.x

  115. 115.

    MacMaster F. P. Carrey N. Sparkes S. Kusumakar V. (2003 ). Proton spectroscopy in medication-free pediatric attention-deficit/hyperactivity disorder. Biol. Psychiatry 53, 184–187

    Not in our library10.1016/s0006-3223(02)01401-4

  116. 116.

    Madsen K. Erritzoe D. Mortensen E. L. Gade A. Madsen J. Baare W. (2011 ). Cognitive function is related to fronto-striatal serotonin transporter levels – a brain PET study in young healthy subjects. Psychopharmacology (Berl.) 213, 573–581

    Not in our library10.1007/s00213-010-1926-4

  117. 117.

    Malison R. T. McDougle C. J. van Dyck C. H. Scahill L. Baldwin R. M. Seibyl J. P. (1995 ). [123I]beta-CIT SPECT imaging of striatal dopamine transporter binding in Tourette’s disorder. Am. J. Psychiatry 152, 1359–1361

    Not in our library10.1176/ajp.152.9.1359

  118. 118.

    Maltby N. Tolin D. F. Worhunsky P. O’Keefe T. M. Kiehl K. A. (2005 ). Dysfunctional action monitoring hyperactivates frontal-striatal circuits in obsessive-compulsive disorder: an event-related fMRI study. Neuroimage 24, 495–503

    Not in our library10.1016/j.neuroimage.2004.08.041

  119. 119.

    Marsh R. Horga G. Parashar N. Wang Z. Peterson B. S. Simpson H. B. (2013 ). Altered activation in fronto-striatal circuits during sequential processing of conflict in unmedicated adults with obsessive-compulsive disorder. Biol. Psychiatry 75, 615–622

    Not in our library10.1016/j.biopsych.2013.02.004

  120. 120.

    Marsh R. Zhu H. Wang Z. Skudlarski P. Peterson B. S. (2007 ). A developmental fMRI study of self-regulatory control in Tourette’s syndrome. Am. J. Psychiatry 164, 955–966

    Not in our library10.1176/appi.ajp.164.6.955

  121. 121.

    Mataix-Cols D. van den Heuvel O. A. (2006 ). Common and distinct neural correlates of obsessive-compulsive and related disorders. Psychiatr. Clin. North Am. 29, 391–410

    Not in our library10.1016/j.psc.2006.02.006

  122. 122.

    McAlonan G. M. Cheung V. Chua S. E. Oosterlaan J. Hung S. F. Tang C. P. (2009 ). Age-related grey matter volume correlates of response inhibition and shifting in attention-deficit hyperactivity disorder. Br. J. Psychiatry 194, 123–129

    Not in our library10.1192/bjp.bp.108.051359

  123. 123.

    Menzies L. Achard S. Chamberlain S. R. Fineberg N. Chen C. H. del Campo N. (2007 ). Neurocognitive endophenotypes of obsessive-compulsive disorder. Brain 130(Pt 12), 3223–3236

    Not in our library10.1093/brain/awm205

  124. 124.

    Mozley L. H. Gur R. C. Mozley P. D. Gur R. E. (2001 ). Striatal dopamine transporters and cognitive functioning in healthy men and women. Am. J. Psychiatry 158, 1492–1499

    Not in our library10.1176/appi.ajp.158.9.1492

  125. 125.

    Muller-Vahl K. R. Berding G. Brucke T. Kolbe H. Meyer G. J. Hundeshagen H. (2000 ). Dopamine transporter binding in Gilles de la Tourette syndrome. J. Neurol. 247, 514–520

    Not in our library10.1007/pl00007806

  126. 126.

    Mulligan R. C. Knopik V. S. Sweet L. H. Fischer M. Seidenberg M. Rao S. M. (2011 ). Neural correlates of inhibitory control in adult attention deficit/hyperactivity disorder: evidence from the Milwaukee longitudinal sample. Psychiatry Res. 194, 119–129

    Not in our library10.1016/j.pscychresns.2011.02.003

  127. 127.

    Nabeyama M. Nakagawa A. Yoshiura T. Nakao T. Nakatani E. Togao O. (2008 ). Functional MRI study of brain activation alterations in patients with obsessive-compulsive disorder after symptom improvement. Psychiatry Res. 163, 236–247

    Not in our library10.1016/j.pscychresns.2007.11.001

  128. 128.

    Nakao T. Nakagawa A. Yoshiura T. Nakatani E. Nabeyama M. Sanematsu H. (2009 ). Duration effect of obsessive-compulsive disorder on cognitive function: a functional MRI study. Depress. Anxiety 26, 814–823

    Not in our library10.1002/da.20484

  129. 129.

    Nakao T. Nakagawa A. Yoshiura T. Nakatani E. Nabeyama M. Yoshizato C. (2005a ). A functional MRI comparison of patients with obsessive-compulsive disorder and normal controls during a Chinese character Stroop task. Psychiatry Res. 139, 101–114

    Not in our library10.1016/j.pscychresns.2004.12.004

  130. 130.

    Nakao T. Nakagawa A. Yoshiura T. Nakatani E. Nabeyama M. Yoshizato C. (2005b ). Brain activation of patients with obsessive-compulsive disorder during neuropsychological and symptom provocation tasks before and after symptom improvement: a functional magnetic resonance imaging study. Biol. Psychiatry 57, 901–910

    Not in our library10.1016/j.biopsych.2004.12.039

  131. 131.

    Nandam L. S. Hester R. Wagner J. Cummins T. D. Garner K. Dean A. J. (2011 ). Methylphenidate but not atomoxetine or citalopram modulates inhibitory control and response time variability. Biol. Psychiatry 69, 902–904

    Not in our library10.1016/j.biopsych.2010.11.014

  132. 132.

    Nandam L. S. Hester R. Wagner J. Dean A. J. Messer C. Honeysett A. (2013 ). Dopamine D(2) receptor modulation of human response inhibition and error awareness. J. Cogn. Neurosci. 25, 649–656

    Not in our library10.1162/jocn_a_00327

  133. 133.

    Nee D. E. Wager T. D. Jonides J. (2007 ). Interference resolution: insights from a meta-analysis of neuroimaging tasks. Cogn. Affect. Behav. Neurosci. 7, 1–17

    Not in our library10.3758/cabn.7.1.1

  134. 134.

    Nigg J. T. (2000 ). On inhibition/disinhibition in developmental psychopathology: views from cognitive and personality psychology and a working inhibition taxonomy. Psychol. Bull. 126, 220–246

    Not in our library10.1037/0033-2909.126.2.220

  135. 135.

    Nymberg C. Jia T. Lubbe S. Ruggeri B. Desrivieres S. Barker G. (2013 ). Neural mechanisms of attention-deficit/hyperactivity disorder symptoms are stratified by MAOA genotype. Biol. Psychiatry 74, 607–614

    Not in our library10.1016/j.biopsych.2013.03.027

  136. 136.

    Oades R. D. Slusarek M. Velling S. Bondy B. (2002 ). Serotonin platelet-transporter measures in childhood attention-deficit/hyperactivity disorder (ADHD): clinical versus experimental measures of impulsivity. World J. Biol. Psychiatry 3, 96–100

    Not in our library10.3109/15622970209150607

  137. 137.

    Olver J. S. O’Keefe G. Jones G. R. Burrows G. D. Tochon-Danguy H. J. Ackermann U. (2009 ). Dopamine D1 receptor binding in the striatum of patients with obsessive-compulsive disorder. J. Affect. Disord. 114, 321–326

    Not in our library10.1016/j.jad.2008.06.020

  138. 138.

    Osinsky R. Schmitz A. Alexander N. Kuepper Y. Kozyra E. Hennig J. (2009 ). TPH2 gene variation and conflict processing in a cognitive and an emotional Stroop task. Behav. Brain Res. 198, 404–410

    Not in our library10.1016/j.bbr.2008.11.022

  139. 139.

    O’Sullivan R. L. Rauch S. L. Breiter H. C. Grachev I. D. Baer L. Kennedy D. N. (1997 ). Reduced basal ganglia volumes in trichotillomania measured via morphometric magnetic resonance imaging. Biol. Psychiatry 42, 39–45

    Not in our library10.1016/s0006-3223(96)00297-1

  140. 140.

    Ozonoff S. Jensen J. (1999 ). Brief report: specific executive function profiles in three neurodevelopmental disorders. J. Autism Dev. Disord. 29, 171–177

    Not in our library10.1023/a:1023052913110

  141. 141.

    Ozonoff S. Strayer D. L. McMahon W. M. Filloux F. (1994 ). Executive function abilities in autism and Tourette syndrome: an information processing approach. J. Child Psychol. Psychiatry 35, 1015–1032

    Not in our library10.1111/j.1469-7610.1994.tb01807.x

  142. 142.

    Page L. A. Rubia K. Deeley Q. Daly E. Toal F. Mataix-Cols D. (2009 ). A functional magnetic resonance imaging study of inhibitory control in obsessive-compulsive disorder. Psychiatry Res. 174, 202–209

    Not in our library10.1016/j.pscychresns.2009.05.002

  143. 143.

    Passamonti L. Fera F. Magariello A. Cerasa A. Gioia M. C. Muglia M. (2006 ). Monoamine oxidase-A genetic variations influence brain activity associated with inhibitory control: new insight into the neural correlates of impulsivity. Biol. Psychiatry 59, 334–340

    Not in our library10.1016/j.biopsych.2005.07.027

  144. 144.

    Passarotti A. M. Sweeney J. A. Pavuluri M. N. (2010 ). Neural correlates of response inhibition in pediatric bipolar disorder and attention deficit hyperactivity disorder. Psychiatry Res. 181, 36–43

    Not in our library10.1016/j.pscychresns.2009.07.002

  145. 145.

    Penades R. Catalan R. Rubia K. Andres S. Salamero M. Gasto C. (2007 ). Impaired response inhibition in obsessive compulsive disorder. Eur. Psychiatry 22, 404–410

    Not in our library10.1016/j.eurpsy.2006.05.001

  146. 146.

    Perani D. Garibotto V. Gorini A. Moresco R. M. Henin M. Panzacchi A. (2008 ). In vivo PET study of 5HT(2A) serotonin and D(2) dopamine dysfunction in drug-naive obsessive-compulsive disorder. Neuroimage 42, 306–314

    Not in our library10.1016/j.neuroimage.2008.04.233

  147. 147.

    Peterson B. S. Potenza M. N. Wang Z. Zhu H. Martin A. Marsh R. (2009 ). An FMRI study of the effects of psychostimulants on default-mode processing during Stroop task performance in youths with ADHD. Am. J. Psychiatry 166, 1286–1294

    Not in our library10.1176/appi.ajp.2009.08050724

  148. 148.

    Peterson B. S. Skudlarski P. Anderson A. W. Zhang H. Gatenby J. C. Lacadie C. M. (1998 ). A functional magnetic resonance imaging study of tic suppression in Tourette syndrome. Arch. Gen. Psychiatry 55, 326–333

    Not in our library10.1001/archpsyc.55.4.326

  149. 149.

    Pliszka S. R. Glahn D. C. Semrud-Clikeman M. Franklin C. Perez R. III Xiong J. (2006 ). Neuroimaging of inhibitory control areas in children with attention deficit hyperactivity disorder who were treatment naive or in long-term treatment. Am. J. Psychiatry 163, 1052–1060

    Not in our library10.1176/appi.ajp.163.6.1052

  150. 150.

    Prince J. (2008 ). Catecholamine dysfunction in attention-deficit/hyperactivity disorder: an update. J. Clin. Psychopharmacol. 28(3 Suppl. 2), S39–S45

    Not in our library10.1097/jcp.0b013e318174f92a

  151. 151.

    Rankins D. Bradshaw J. L. Georgiou-Karistianis N. (2006 ). The semantic Simon effect in Tourette’s syndrome and obsessive-compulsive disorder. Brain Cogn. 61, 225–234

    Not in our library10.1016/j.bandc.2006.01.002

  152. 152.

    Ray Li C. S. Chang H. L. Hsu Y. P. Wang H. S. Ko N. C. (2006 ). Motor response inhibition in children with Tourette’s disorder. J. Neuropsychiatry Clin. Neurosci. 18, 417–419

    Not in our library10.1176/appi.neuropsych.18.3.417

  153. 153.

    Raz A. Zhu H. Yu S. Bansal R. Wang Z. Alexander G. M. (2009 ). Neural substrates of self-regulatory control in children and adults with Tourette syndrome. Can. J. Psychiatry 54, 579–588

    Not in our library10.1177/070674370905400902

  154. 154.

    Robbins T. W. (2007 ). Shifting and stopping: fronto-striatal substrates, neurochemical modulation and clinical implications. Philos. Trans. R. Soc. Lond. B Biol. Sci. 362, 917–932

    Not in our library10.1098/rstb.2007.2097

  155. 155.

    Robertson M. M. (2008 ). The prevalence and epidemiology of Gilles de la Tourette syndrome. Part 1: the epidemiological and prevalence studies. J. Psychosom. Res. 65, 461–472

    Not in our library10.1016/j.jpsychores.2008.03.006

  156. 156.

    Robertson M. M. (2011 ). Gilles de la Tourette syndrome: the complexities of phenotype and treatment. Br. J. Hosp. Med. (Lond) 72, 100–107

    Not in our library10.12968/hmed.2011.72.2.100

  157. 157.

    Roesch-Ely D. Scheffel H. Weiland S. Schwaninger M. Hundemer H. P. Kolter T. (2005 ). Differential dopaminergic modulation of executive control in healthy subjects. Psychopharmacology (Berl.) 178, 420–430

    Not in our library10.1007/s00213-004-2027-z

  158. 158.

    Roessner V. Plessen K. J. Rothenberger A. Ludolph A. G. Rizzo R. Skov L. (2011 ). European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment. Eur. Child Adolesc. Psychiatry 20, 173–196

    Not in our library10.1007/s00787-011-0163-7

  159. 159.

    Roth R. M. Saykin A. J. Flashman L. A. Pixley H. S. West J. D. Mamourian A. C. (2007 ). Event-related functional magnetic resonance imaging of response inhibition in obsessive-compulsive disorder. Biol. Psychiatry 62, 901–909

    Not in our library10.1016/j.biopsych.2006.12.007

  160. 160.

    Rubia K. Cubillo A. Smith A. B. Woolley J. Heyman I. Brammer M. J. (2010 ). Disorder-specific dysfunction in right inferior prefrontal cortex during two inhibition tasks in boys with attention-deficit hyperactivity disorder compared to boys with obsessive-compulsive disorder. Hum. Brain Mapp. 31, 287–299

    Not in our library10.1002/hbm.20864

  161. 161.

    Rubia K. Cubillo A. Woolley J. Brammer M. J. Smith A. (2011a ). Disorder-specific dysfunctions in patients with attention-deficit/hyperactivity disorder compared to patients with obsessive-compulsive disorder during interference inhibition and attention allocation. Hum. Brain Mapp. 32, 601–611

    Not in our library10.1002/hbm.21048

  162. 162.

    Rubia K. Halari R. Cubillo A. Smith A. B. Mohammad A. M. Brammer M. (2011b ). Methylphenidate normalizes fronto-striatal underactivation during interference inhibition in medication-naive boys with attention-deficit hyperactivity disorder. Neuropsychopharmacology 36, 1575–1586

    Not in our library10.1038/npp.2011.30

  163. 163.
    Methylphenidate Normalizes Frontocingulate Underactivation During Error Processing in Attention-Deficit/Hyperactivity Disorder · 2011
    No notice
  164. 164.

    Rubia K. Lee F. Cleare A. J. Tunstall N. Fu C. H. Brammer M. (2005a ). Tryptophan depletion reduces right inferior prefrontal activation during response inhibition in fast, event-related fMRI. Psychopharmacology (Berl.) 179, 791–803

    Not in our library10.1007/s00213-004-2116-z

  165. 165.

    Rubia K. Overmeyer S. Taylor E. Brammer M. Williams S. C. Simmons A. (1999 ). Hypofrontality in attention deficit hyperactivity disorder during higher-order motor control: a study with functional MRI. Am. J. Psychiatry 156, 891–896

    Not in our library10.1176/ajp.156.6.891

  166. 166.

    Rubia K. Russell T. Overmeyer S. Brammer M. J. Bullmore E. T. Sharma T. (2001 ). Mapping motor inhibition: conjunctive brain activations across different versions of go/no-go and stop tasks. Neuroimage 13, 250–261

    Not in our library10.1006/nimg.2000.0685

  167. 167.

    Rubia K. Smith A. B. Brammer M. J. Toone B. Taylor E. (2005b ). Abnormal brain activation during inhibition and error detection in medication-naive adolescents with ADHD. Am. J. Psychiatry 162, 1067–1075

    Not in our library10.1176/appi.ajp.162.6.1067

  168. 168.

    Ruscio A. M. Stein D. J. Chiu W. T. Kessler R. C. (2010 ). The epidemiology of obsessive-compulsive disorder in the national comorbidity survey replication. Mol. Psychiatry 15, 53–63

    Not in our library10.1038/mp.2008.94

  169. 169.

    Schachar R. Logan G. D. Robaey P. Chen S. Ickowicz A. Barr C. (2007 ). Restraint and cancellation: multiple inhibition deficits in attention deficit hyperactivity disorder. J. Abnorm. Child Psychol. 35, 229–238

    Not in our library10.1007/s10802-006-9075-2

  170. 170.

    Schlosser R. G. Wagner G. Schachtzabel C. Peikert G. Koch K. Reichenbach J. R. (2010 ). Fronto-cingulate effective connectivity in obsessive compulsive disorder: a study with fMRI and dynamic causal modeling. Hum. Brain Mapp. 31, 1834–1850

    Not in our library10.1002/hbm.20980

  171. 171.

    Schmitt J. A. Jorissen B. L. Sobczak S. van Boxtel M. P. Hogervorst E. Deutz N. E. (2000 ). Tryptophan depletion impairs memory consolidation but improves focussed attention in healthy young volunteers. J. Psychopharmacol. 14, 21–29

    Not in our library10.1177/026988110001400102

  172. 172.

    Scholes K. E. Harrison B. J. O’Neill B. V. Leung S. Croft R. J. Pipingas A. (2007 ). Acute serotonin and dopamine depletion improves attentional control: findings from the Stroop task. Neuropsychopharmacology 32, 1600–1610

    Not in our library10.1038/sj.npp.1301262

  173. 173.

    Schulz K. P. Fan J. Tang C. Y. Newcorn J. H. Buchsbaum M. S. Cheung A. M. (2004 ). Response inhibition in adolescents diagnosed with attention deficit hyperactivity disorder during childhood: an event-related FMRI study. Am. J. Psychiatry 161, 1650–1657

    Not in our library10.1176/appi.ajp.161.9.1650

  174. 174.

    Sebastian A. Baldermann C. Feige B. Katzev M. Scheller E. Hellwig B. (2013a ). Differential effects of age on subcomponents of response inhibition. Neurobiol. Aging 34, 2183–2193

    Not in our library10.1016/j.neurobiolaging.2013.03.013

  175. 175.

    Sebastian A. Gerdes B. Feige B. Kloppel S. Lange T. Philipsen A. (2012 ). Neural correlates of interference inhibition, action withholding and action cancelation in adult ADHD. Psychiatry Res. 202, 132–141

    Not in our library10.1016/j.pscychresns.2012.02.010

  176. 176.

    Sebastian A. Pohl M. F. Kloppel S. Feige B. Lange T. Stahl C. (2013b ). Disentangling common and specific neural subprocesses of response inhibition. Neuroimage 64, 601–615

    Not in our library10.1016/j.neuroimage.2012.09.020

  177. 177.

    Serra-Mestres J. Ring H. A. Costa D. C. Gacinovic S. Walker Z. Lees A. J. (2004 ). Dopamine transporter binding in Gilles de la Tourette syndrome: a [123I]FP-CIT/SPECT study. Acta Psychiatr. Scand. 109, 140–146

    Not in our library10.1111/j.0001-690x.2004.00214.x

  178. 178.

    Shaw P. Gornick M. Lerch J. Addington A. Seal J. Greenstein D. (2007 ). Polymorphisms of the dopamine D4 receptor, clinical outcome, and cortical structure in attention-deficit/hyperactivity disorder. Arch. Gen. Psychiatry 64, 921–931

    Not in our library10.1001/archpsyc.64.8.921

  179. 179.

    Silveri M. M. Sneider J. T. Crowley D. J. Covell M. J. Acharya D. Rosso I. M. (2013 ). Frontal lobe gamma-aminobutyric acid levels during adolescence: associations with impulsivity and response inhibition. Biol. Psychiatry 74, 296–304

    Not in our library10.1016/j.biopsych.2013.01.033

  180. 180.

    Singer H. S. Szymanski S. Giuliano J. Yokoi F. Dogan A. S. Brasic J. R. (2002 ). Elevated intrasynaptic dopamine release in Tourette’s syndrome measured by PET. Am. J. Psychiatry 159, 1329–1336

    Not in our library10.1176/appi.ajp.159.8.1329

  181. 181.

    Smith A. B. Taylor E. Brammer M. Toone B. Rubia K. (2006 ). Task-specific hypoactivation in prefrontal and temporoparietal brain regions during motor inhibition and task switching in medication-naive children and adolescents with attention deficit hyperactivity disorder. Am. J. Psychiatry 163, 1044–1051

    Not in our library10.1176/appi.ajp.163.6.1044

  182. 182.

    Solis-Ortiz S. Perez-Luque E. Morado-Crespo L. Gutierrez-Munoz M. (2010 ). Executive functions and selective attention are favored in middle-aged healthy women carriers of the Val/Val genotype of the catechol-O-methyltransferase gene: a behavioral genetic study. Behav. Brain Funct. 6, 67

    Not in our library10.1186/1744-9081-6-67

  183. 183.

    Sowell E. R. Thompson P. M. Welcome S. E. Henkenius A. L. Toga A. W. Peterson B. S. (2003 ). Cortical abnormalities in children and adolescents with attention-deficit hyperactivity disorder. Lancet 362, 1699–1707

    Not in our library10.1016/s0140-6736(03)14842-8

  184. 184.

    Spinelli S. Joel S. Nelson T. E. Vasa R. A. Pekar J. J. Mostofsky S. H. (2011 ). Different neural patterns are associated with trials preceding inhibitory errors in children with and without attention-deficit/hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry 50, 705.e–715.e

    Not in our library10.1016/j.jaac.2011.03.014

  185. 185.

    Stanley M. A. Breckenridge J. K. Swann A. C. Freeman E. B. Reich L. (1997a ). Fluvoxamine treatment of trichotillomania. J. Clin. Psychopharmacol. 17, 278–283

    Not in our library10.1097/00004714-199708000-00007

  186. 186.

    Stanley M. A. Hannay H. J. Breckenridge J. K. (1997b ). The neuropsychology of trichotillomania. J. Anxiety Disord. 11, 473–488

    Not in our library10.1016/s0887-6185(97)00024-8

  187. 187.

    Starck G. Ljungberg M. Nilsson M. Jonsson L. Lundberg S. Ivarsson T. (2008 ). A 1H magnetic resonance spectroscopy study in adults with obsessive compulsive disorder: relationship between metabolite concentrations and symptom severity. J. Neural Transm. 115, 1051–1062

    Not in our library10.1007/s00702-008-0045-4

  188. 188.

    Steeves T. D. Fox S. H. (2008 ). Neurobiological basis of serotonin-dopamine antagonists in the treatment of Gilles de la Tourette syndrome. Prog. Brain Res. 172, 495–513

    Not in our library10.1016/s0079-6123(08)00924-2

  189. 189.

    Steeves T. D. Ko J. H. Kideckel D. M. Rusjan P. Houle S. Sandor P. (2010 ). Extrastriatal dopaminergic dysfunction in Tourette syndrome. Ann. Neurol. 67, 170–181

    Not in our library10.1002/ana.21809

  190. 190.

    Stein D. J. Bouwer C. Maud C. M. (1997 ). Use of the selective serotonin reuptake inhibitor citalopram in treatment of trichotillomania. Eur. Arch. Psychiatry Clin. Neurosci. 247, 234–236

    Not in our library10.1007/bf02900220

  191. 191.

    Stoltenberg S. F. Glass J. M. Chermack S. T. Flynn H. A. Li S. Weston M. E. (2006 ). Possible association between response inhibition and a variant in the brain-expressed tryptophan hydroxylase-2 gene. Psychiatr. Genet. 16, 35–38

    Not in our library10.1097/01.ypg.0000176528.30362.34

  192. 192.

    Streichenwein S. M. Thornby J. I. (1995 ). A long-term, double-blind, placebo-controlled crossover trial of the efficacy of fluoxetine for trichotillomania. Am. J. Psychiatry 152, 1192–1196

    Not in our library10.1176/ajp.152.8.1192

  193. 193.

    Sukhodolsky D. G. Landeros-Weisenberger A. Scahill L. Leckman J. F. Schultz R. T. (2010 ). Neuropsychological functioning in children with Tourette syndrome with and without attention-deficit/hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry 49, 1155–1164

    Not in our library10.1016/j.jaac.2010.08.008

  194. 194.

    Suskauer S. J. Simmonds D. J. Fotedar S. Blankner J. G. Pekar J. J. Denckla M. B. (2008 ). Functional magnetic resonance imaging evidence for abnormalities in response selection in attention deficit hyperactivity disorder: differences in activation associated with response inhibition but not habitual motor response. J. Cogn. Neurosci. 20, 478–493

    Not in our library10.1162/jocn.2008.20032

  195. 195.

    Swain J. E. Scahill L. Lombroso P. J. King R. A. Leckman J. F. (2007 ). Tourette syndrome and tic disorders: a decade of progress. J. Am. Acad. Child Adolesc. Psychiatry 46, 947–968

    Not in our library10.1097/chi.0b013e318068fbcc

  196. 196.

    Swick D. Ashley V. Turken U. (2011 ). Are the neural correlates of stopping and not going identical? Quantitative meta-analysis of two response inhibition tasks. Neuroimage 56, 1655–1665

    Not in our library10.1016/j.neuroimage.2011.02.070

  197. 197.

    Tamm L. Menon V. Ringel J. Reiss A. L. (2004 ). Event-related FMRI evidence of frontotemporal involvement in aberrant response inhibition and task switching in attention-deficit/hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry 43, 1430–1440

    Not in our library10.1097/01.chi.0000140452.51205.8d

  198. 198.

    Thompson J. Thomas N. Singleton A. Piggott M. Lloyd S. Perry E. K. (1997 ). D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics 7, 479–484

    Not in our library10.1097/00008571-199712000-00006

  199. 199.

    Turner D. C. Robbins T. W. Clark L. Aron A. R. Dowson J. Sahakian B. J. (2003 ). Cognitive enhancing effects of modafinil in healthy volunteers. Psychopharmacology (Berl.) 165, 260–269

    Not in our library10.1007/s00213-002-1250-8

  200. 200.

    Vaidya C. J. Austin G. Kirkorian G. Ridlehuber H. W. Desmond J. E. Glover G. H. (1998 ). Selective effects of methylphenidate in attention deficit hyperactivity disorder: a functional magnetic resonance study. Proc. Natl. Acad. Sci. U.S.A. 95, 14494–14499

    Not in our library10.1073/pnas.95.24.14494

  201. 201.

    Vaidya C. J. Bunge S. A. Dudukovic N. M. Zalecki C. A. Elliott G. R. Gabrieli J. D. (2005 ). Altered neural substrates of cognitive control in childhood ADHD: evidence from functional magnetic resonance imaging. Am. J. Psychiatry 162, 1605–1613

    Not in our library10.1176/appi.ajp.162.9.1605

  202. 202.

    Van Ameringen M. Mancini C. Patterson B. Bennett M. Oakman J. (2010 ). A randomized, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania. J. Clin. Psychiatry 71, 1336–1343

    Not in our library10.4088/jcp.09m05114gre

  203. 203.

    van den Heuvel O. A. Veltman D. J. Groenewegen H. J. Witter M. P. Merkelbach J. Cath D. C. (2005 ). Disorder-specific neuroanatomical correlates of attentional bias in obsessive-compulsive disorder, panic disorder, and hypochondriasis. Arch. Gen. Psychiatry 62, 922–933

    Not in our library10.1001/archpsyc.62.8.922

  204. 204.

    van der Wee N. J. Stevens H. Hardeman J. A. Mandl R. C. Denys D. A. van Megen H. J. (2004 ). Enhanced dopamine transporter density in psychotropic-naive patients with obsessive-compulsive disorder shown by [123I]{beta}-CIT SPECT. Am. J. Psychiatry 161, 2201–2206

    Not in our library10.1176/appi.ajp.161.12.2201

  205. 205.

    van Minnen A. Hoogduin K. A. Keijsers G. P. Hellenbrand I. Hendriks G. J. (2003 ). Treatment of trichotillomania with behavioral therapy or fluoxetine: a randomized, waiting-list controlled study. Arch. Gen. Psychiatry 60, 517–522

    Not in our library10.1001/archpsyc.60.5.517

  206. 206.

    Vasic N. Plichta M. M. Wolf R. C. Fallgatter A. J. Sosic-Vasic Z. Gron G. (2012 ). Reduced neural error signaling in left inferior prefrontal cortex in young adults with ADHD. J. Atten. Disord.

    Not in our library10.1177/1087054712446172

  207. 207.

    Verte S. Geurts H. M. Roeyers H. Oosterlaan J. Sergeant J. A. (2005 ). Executive functioning in children with autism and Tourette syndrome. Dev. Psychopathol. 17, 415–445

    Not in our library10.1017/s0954579405050200

  208. 208.

    Viard A. Flament M. F. Artiges E. Dehaene S. Naccache L. Cohen D. (2005 ). Cognitive control in childhood-onset obsessive-compulsive disorder: a functional MRI study. Psychol. Med. 35, 1007–1017

    Not in our library10.1017/s0033291704004295

  209. 209.

    Volkow N. D. Gur R. C. Wang G. J. Fowler J. S. Moberg P. J. Ding Y. S. (1998 ). Association between decline in brain dopamine activity with age and cognitive and motor impairment in healthy individuals. Am. J. Psychiatry 155, 344–349

    Not in our library10.1176/ajp.155.3.344

  210. 210.

    Vollm B. Richardson P. McKie S. Elliott R. Deakin J. F. Anderson I. M. (2006 ). Serotonergic modulation of neuronal responses to behavioural inhibition and reinforcing stimuli: an fMRI study in healthy volunteers. Eur. J. Neurosci. 23, 552–560

    Not in our library10.1111/j.1460-9568.2005.04571.x

  211. 211.

    Vriend C. Pattij T. van der Werf Y. D. Voorn P. Booij J. Rutten S. (2014 ). Depression and impulse control disorders in Parkinson’s disease: two sides of the same coin? Neurosci. Biobehav. Rev. 38, 60–71

    Not in our library10.1016/j.neubiorev.2013.11.001

  212. 212.

    Wager T. D. Sylvester C. Y. Lacey S. C. Nee D. E. Franklin M. Jonides J. (2005 ). Common and unique components of response inhibition revealed by fMRI. Neuroimage 27, 323–340

    Not in our library10.1016/j.neuroimage.2005.01.054

  213. 213.

    Walther D. J. Bader M. (2003 ). A unique central tryptophan hydroxylase isoform. Biochem. Pharmacol. 66, 1673–1680

    Not in our library10.1016/s0006-2952(03)00556-2

  214. 214.

    Wang G.-J. Volkow N. D. Wigal T. Kollins S. H. Newcorn J. H. Telang F. (2013 ). Long-term stimulant treatment affects brain dopamine transporter level in patients with attention deficit hyperactive disorder. PLoS ONE 8:e63023

    Not in our library10.1371/journal.pone.0063023

  215. 215.

    Watkins L. H. Sahakian B. J. Robertson M. M. Veale D. M. Rogers R. D. Pickard K. M. (2005 ). Executive function in Tourette’s syndrome and obsessive-compulsive disorder. Psychol. Med. 35, 571–582

    Not in our library10.1017/s0033291704003691

  216. 216.

    White M. J. Morris C. P. Lawford B. R. Young R. M. (2008 ). Behavioral phenotypes of impulsivity related to the ANKK1 gene are independent of an acute stressor. Behav. Brain Funct. 4, 54

    Not in our library10.1186/1744-9081-4-54

  217. 217.

    White M. P. Koran L. M. (2011 ). Open-label trial of aripiprazole in the treatment of trichotillomania. J. Clin. Psychopharmacol. 31, 503–506

    Not in our library10.1097/jcp.0b013e318221b1ba

  218. 218.

    Wong D. F. Brasic J. R. Singer H. S. Schretlen D. J. Kuwabara H. Zhou Y. (2008 ). Mechanisms of dopaminergic and serotonergic neurotransmission in Tourette syndrome: clues from an in vivo neurochemistry study with PET. Neuropsychopharmacology 33, 1239–1251

    Not in our library10.1038/sj.npp.1301528

  219. 219.

    Woolley J. Heyman I. Brammer M. Frampton I. McGuire P. K. Rubia K. (2008 ). Brain activation in paediatric obsessive compulsive disorder during tasks of inhibitory control. Br. J. Psychiatry 192, 25–31

    Not in our library10.1192/bjp.bp.107.036558

  220. 220.

    Wylie S. A. Claassen D. O. Kanoff K. E. Ridderinkhof K. R. van den Wildenberg W. P. (2013 ). Impaired inhibition of prepotent motor actions in patients with Tourette syndrome. J. Psychiatry Neurosci. 38, 349–356

    Not in our library10.1503/jpn.120138

Cited by papers we hold 2

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.